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Inadequate insulin secretion is an important facet of Type II diabetes (T2D). 
Pancreatic beta cells release insulin in response to signals derived from 
glucose metabolism. While glucose is the major stimulus for insulin secretion, 
intracellular cyclic adenosine monophosphate (cAMP) signal generated by 
secretagogues like glucagon-like peptide 1 (GLP-1) is crucial in potentiation 
of insulin secretion. GLP-1 modulates exocytosis by coordinating protein 
kinase A (PKA)-dependent phosphorylation of proteins in exocytosis 
machinery and PKA-independent activation of cAMP-regulated guanine 
nucleotide exchange factor (GEF/EPAC) signaling. GLP-1 based drugs are 
being widely used to potentiate insulin secretion and improve metabolic 
control in diabetics; however, molecular mechanisms underlying GLP-1 
potentiation of insulin secretion remain unclear. Synaptotagmin7 (Syt7), a 
principle calcium sensor for insulin secretion in beta cells, is a 
phosphorylation substrate of PKA. Phosphorylation of Syt7 is essential for 
GLP-1 potentiation of insulin release, given that phosphoinactive form of Syt7 
fails to elicit an enhancement in insulin secretion in response to exendin-4, a 
potent GLP-1 receptor agonist. Using proteomic screening, Rabphilin3a 
(Rph3a) - a Rab effector protein was identified as a novel phosphorylation 
dependent Syt7 binding protein. By performing pull-down assays using 
phosphomimetic and phosphoinactive forms of GST-Syt7, it was further 
confirmed that Syt7 binds to Rph3a in a calcium and phosphorylation 
dependent manner. Treatment of insulin-secreting MIN6 cells with a cAMP 
analogue induces in vivo phosphorylation of these proteins and enhances 
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Rph3a-Syt7 interaction. Interestingly, knockdown of endogenous Rph3a in 
MIN6 cells results in diminished GLP-1 potentiated insulin release, while the 
overexpression of phosphomimetic Rph3a (S234E) in the primary mouse islets 
enhances GLP-1 potentiation of insulin secretion. This suggests that Rph3a is 
directly involved in GLP-1 dependent insulin release. Finally, motor protein 
Myosin-Va (MyoVa) has been demonstrated to coimmunoprecipitate together 
with Syt7 and Rph3a upon activation of PKA signaling. Furthermore, 
knockdown of MyoVa decreases GLP-1 dependent insulin release, which 
correlates with its known role in granule trafficking. Collectively, these 
findings provide mechanistic insights in supporting enhanced insulin secretory 
granule exocytosis following phosphorylation of both Syt7 and its interacting 
proteins by PKA.  
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Chapter 1 INTRODUCTION 
1.1 Overview 
Diabetes mellitus, a global health problem affects more than 8% of the world 
population and by 2035, the number of diabetics is expected to rise as high as 
592 million (International Diabetes Federation, 2014). Diabetes is a metabolic 
disorder characterized by chronic hyperglycemia resulting from defects in 
insulin secretion and its action. Insulin is a blood glucose-lowering hormone 
produced by pancreatic beta cells. The primary role of beta cell is to achieve 
metabolic homeostasis by coupling ambient glucose levels in blood with 
insulin secretion. Insulin lowers blood glucose level by stimulating glucose 
uptake from the peripheral tissues while inhibiting glucose production from 
liver. In type I diabetes, the pancreatic beta cells are progressively lost by 
autoimmune-mediate assault (Morgan, Leete, Foulis, & Richardson, 2014). 
Mostly common in children, it accounts for 5-10% of diabetics and is often 
treated with daily injections of insulin to control blood glucose level. On the 
contrary, Type II diabetes (T2D) is characterized by insulin resistance in the 
peripheral tissues and beta cell dysfunction and accounts for almost 90% of all 
diabetics. Insulin resistance is strongly related to visceral obesity and low-
grade chronic inflammation (Tsatsoulis, Mantzaris, Bellou, & Andrikoula, 
2013). While changes in diet and lifestyle are key drivers of diabetes 
pandemic, heritable factors also contribute to significant proportion of the 
disease (Hu, 2011). Standard treatment regimens thus include lifestyle changes 
together with drugs that stimulate release of endogenous insulin and/or 
increase peripheral insulin sensitivity (American Diabetes Association, 2014). 
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Although insulin resistance is a hallmark of T2D, in early stages of obesity, 
insulin resistance is often insufficient to cause hyperglycemia; as their 
pancreatic beta cell counteracts this by increasing insulin secretion and beta 
cell mass. Only when this adaptation fails, as a result of prolonged oxidative 
and endoplasmic reticulum stress and/or activation of pro-inflammatory 
pathways, diabetes ensues (Ahren, 2005; Prentki & Nolan, 2006). Thus, beta 
cell dysfunction remains at the core of diabetes determinant. Indeed, genome 
wide association studies (GWAS) also point to correlation between genetic 
variants associated with diabetes and defects in insulin secretion (Dupuis et 
al., 2010; Scott et al., 2012; Sladek et al., 2007; Strawbridge et al., 2011). 
Henceforth, understanding the molecular mechanism underlying defective 
insulin release not only provides a better understanding of the pathophysiology 
of diabetes mellitus but also provides impetus for developing better 
therapeutics for T2D. 
 
Glucagon-like peptide (GLP-1), an incretin hormone lowers postprandial 
blood glucose by acting on beta cells to enhance insulin secretion in glucose-
dependent manner. Thus, GLP-1 analogues are now widely used to treat 
patients with type II diabetes. However, besides lowering blood glucose, GLP-
1 also regulates diverse physiological responses by increasing global cAMP 
level (Baggio & Drucker, 2007) which might result in various side effects 
when used as therapeutic agent. Besides, GLP-1 also has proliferative effect in 
beta cells which in long run can trigger pancreatitis or pancreatic cancer (Cure, 
Pileggi, & Alejandro, 2008; Denker & Dimarco, 2006). A challenge 
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henceforth is to understand the molecular targets downstream of GLP-1 in 
order to harness its blood glucose lowering effect and avoid other deleterious 
effect such as global cAMP elevation. Insights have come from studying the 
unique substrate of GLP-1 in the beta cells that may provide valuable insights 
and translatable information for drug design. In this thesis, I attempt to 
understand the molecular mechanism underlying GLP-1 potentiated insulin 
secretion, using recently identified GLP-1 substrate (Synaptotagmin-7) in beta 
cell. In this introduction section, I would like to elaborate on the general 
mechanisms of glucose and GLP-1 dependent insulin secretion and the 
molecular players involved in exocytosis of insulin granules. 
 
1.2 Mechanisms of glucose-induced insulin secretion 
Insulin is a peptide hormone produced exclusively by the beta cells in 
pancreatic islet. It is packaged and stored in dense core vesicles within the beta 
cells. Release of insulin in bloodstream thus requires fusion of these vesicles 
with the plasma membrane, which is a tightly regulated process. Increase in 
blood glucose concentration is the major trigger for insulin release from the 
vesicles. Beta cell serves as a mediator to couple changes in membrane 
potential brought about by glucose metabolism to exocytosis of insulin 
granules (Ashcroft & Rorsman, 1989). Under low glucose, a negative 
membrane potential (-70 mV) is maintained in the beta cell via a continuous 
outward flux of positively charged potassium ions (Ashcroft & Rorsman, 
1989). After food intake, glucose is taken up by the beta cells via glucose 
transporters (GLUTs). While GLUT2 is the major isoform in rodent beta cell, 
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GLUT1 and GLUT3 predominate in human islets (McCulloch et al., 2011). 
Glucose is ultimately oxidized to generate high-energy intracellular adenosine 
triphosphate (ATP). The increased intracellular ATP/adenosine diphosphate 
(ADP) ratio within the beta cell inhibits potassium permeability by closing the 
ATP-sensitive potassium channels. This leads to an accumulation of positively 
charged ions inside the cells that triggers membrane depolarization and 
subsequent opening of voltage dependent calcium L-channels. Opening of 
calcium channels causes a rapid spike in free cytosolic calcium ions, thereby 
triggering exocytosis of insulin from the secretory granules (Ashcroft & 
Rorsman, 2012). Figure 1-1 shows the illustration of mechanisms involved in 
glucose dependent insulin secretion. While glucose triggers insulin granule 
exocytosis, various nutritional (free fatty acids and amino acids) and hormonal 
(GLP-1, adrenaline, cholecystokinin) secretagogues further potentiate insulin 






Figure 1-1 Mechanism of insulin secretion from pancreatic beta cells 
 
Glucose enters pancreatic beta cells via glucose transporter (GLUT), gets 
metabolized to produce ATP. Rise in ATP/ADP ratio inhibits potassium 
channel resulting in membrane depolarization and opening of voltage gated 
calcium channel (VDCC). Sudden rise in calcium concentration inside the cell 
as a result of calcium influx triggers release of insulin from the secretory 
granules. Extracellular signals acting on G-protein coupled receptors in the 
beta cell membrane activate secondary messengers to further potentiate insulin 
release. (Adapted form (Ahren, 2009)) 
 
Although the molecular mechanisms of extracellular glucose sensing 
cumulating to insulin secretion has deepened remarkably in the recent years 
(Ashcroft & Rorsman, 2012), insulin secretion is a multifaceted process and 
the final steps in the insulin granule secretory process still remains elusive. 
Exocytosis of these granules from the secretory vesicle requires highly 
regulated multiple morphologically and functionally defined stages that 
includes recruitment of vesicles, its tethering and docking to the plasma 
membrane, priming to fusion machinery followed by calcium triggered 
6 
 
membrane fusion (Burgess & Kelly, 1987). Tethering involves recruiting the 
vesicles from the cytosolic depot to the plasma membrane. Once in the plasma 
membrane, the lipid bilayers of the vesicle membrane interact with the plasma 
membrane whereby the vesicle is assumed to be docked. Following docking, 
the vesicles are primed via an ATP-dependent step such that an increase in 
intracellular calcium can immediately result in fusion and granule release 
(Burgoyne & Morgan, 2003; Jahn & Fasshauer, 2012; Sudhof, 2013b).  
 
1.3 Dynamics of insulin secretion 
Glucose uptake causes a biphasic secretion of insulin. During the first minutes, 
insulin is rapidly secreted that accounts to about 2-3% of beta cell insulin 
content. This phase is followed by lower but long lasting secretion phase 
accounting for about 20% of total insulin content. Ultrastructural and 
biochemical studies together with electrophysiological measurements have 
revealed two distinct populations of insulin granules. The biphasic insulin 
response is thought to be mediated by these functionally distinct pools of 
insulin granules, the first phase being contributed by granules in the readily 
releasable pool close to the membrane followed by sustained phase resulting 
from mobilization of granules along the microtubules from the reserve pool 
alongside remodeling of filamentous actin (Rorsman & Renstrom, 2003; Z. 
Wang & Thurmond, 2009). This classical model has however been recently 
challenged by the observation in total internal reflective fluorescence 
microscopy (TIRFM) that the first phase also involves “newcomer” secretory 
granules suddenly appearing at the plasma membrane that undergo exocytosis 
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without any time delay pertaining to docking (Nagamatsu, Ohara-Imaizumi, 
Nakamichi, Kikuta, & Nishiwaki, 2006; Ohara-Imaizumi et al., 2007; 
Shibasaki et al., 2007). Many more studies report that newcomer granules 
contribute to both phases of insulin release (Yasuda et al., 2010; Zhu et al., 
2015), questioning the requirement of stable docking for fusion. In fact, 
evidences also suggest that docking might even constrain granule fusion 
(Gomi, Mizutani, Kasai, Itohara, & Izumi, 2005; Kasai, Fujita, Gomi, & 
Izumi, 2008). Henceforth, mobility of granules to the membrane seems to be a 
critical factor for increasing probability of fusion and exocytosis (Allersma, 
Bittner, Axelrod, & Holz, 2006; Degtyar, Allersma, Axelrod, & Holz, 2007; 
Verhage & Sorensen, 2008).  
 
1.4 Molecular machinery for insulin granule exocytosis 
Regulated exocytosis involves multitude of events beginning with the 
synthesis of preproinsulin in the endoplasmic reticulum, followed by budding 
of immature insulin granules from the trans-golgi network, maturation of 
granules and the final fusion of release competent granules from the plasma 
membrane. The proteins in exocytosis machinery tightly regulate these 
discrete cascades of events. Similar to neurons and neuroendocrine cells 
(Seino & Shibasaki, 2005; Sudhof, 2004), the essential proteins in fusion 
machinery comprise of Soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor (SNARE) proteins, calcium sensors and regulatory proteins. 
Their involvement and interaction in facilitating insulin granule exocytosis 





Figure 1-2 Molecular players involved in insulin granule exocytosis 
SNARE complex comprising the syntaxin, SNAP-25 and synaptobrevin form 
the minimal machinery for fusion. Increase in calcium concentration inside the 
cell is sensed by C2 domain protein-synaptotagmins. Numerous other 
conserved proteins like Munc proteins, Rab and their effectors aid in granule 
trafficking and fusion steps. 
 
1.4.1 Soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) 
SNARE proteins comprising of syntaxin-1A and SNAP-25 at the plasma 
membrane and vesicle-associated membrane protein (VAMP) or 
synaptobrevin at the vesicular membrane represent the minimal machinery for 
vesicle fusion in all eukaryotic cells (Weber et al., 1998). The defining feature 
of the core components comprising the SNAREs is the presence of SNARE 
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motif which is composed of about sixty amino acids and has a high tendency 
to form coiled coil domains (Jahn & Sudhof, 1999; Rizo & Sudhof, 2002). 
Upon contact, SNAREs on opposed membranes form a tight four-helix bundle 
involving one SNARE motif from synaptobrevin, one from syntaxin and two 
SNARE motifs from SNAP-25. This pulls the opposing membranes together 
and the energy released during this assembly initiates membrane fusion 
(Sutton, Fasshauer, Jahn, & Brunger, 1998). 
 
Various SNARE isoforms have been reported in pancreatic beta cells (Jewell, 
Oh, & Thurmond, 2010). The major SNARE isoforms involved in insulin 
secretion following glucose stimuli involves same SNARE isoforms as 
reported for synaptic vesicle exocytosis, namely, syntaxin-1, SNAP-25 and 
VAMP2 suggesting their conserved universal role in granule exocytosis. Other 
isoforms are suggested to play a role in providing specificity to vesicle 
targeting in various modes of insulin granule exocytosis such as recruitment of 
newcomer secretory granules and granule-granule fusion (Gaisano, 2012; 
Kasai et al., 2008; McNew et al., 2000; Shibasaki et al., 2007; Yasuda et al., 
2010). In line with this, Zhu et al and authors demonstrated that syntaxin-1A 
co-immunoprecipitated abundant SNAP-25, SNAP-23 and VAMP-2 whereas 
syntaxin-2 and -3 immunoprecipitated abundant Munc18b under basal 
condition. However, when stimulated with high glucose and GLP-1, syntaxin-
2 and -3 co-immunoprecipitated abundant SNAP-25, SNAP-23 and VAMP-8, 
indicating a preferential isoform binding following activation by different 
stimuli (Zhu et al., 2012). 
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The importance of the SNARE complex in insulin granule exocytosis has been 
documented in several prominent studies (Eliasson et al., 2008; Gerber & 
Sudhof, 2002; Kiraly-Borri et al., 1996; Wheeler et al., 1996). Most 
importantly, Syntaxin-1A and SNAP-25 proteins remain as clusters in close 
association with the insulin granules near the plasma membrane of beta cells 
to facilitate insulin granule exocytosis. These proteins are significantly 
reduced in Goto-Kakizaki (GK) rats, a non-obese Wistar rat substrain that 
develops T2D early in life (Nagamatsu et al., 1999) and in pancreatic islets of 
human T2D patients (Andersson et al., 2012; Ostenson, Gaisano, Sheu, Tibell, 
& Bartfai, 2006). In line with this, Syntaxin-1A null mice display fewer 
docked granules and consequently impaired first phase insulin release 
indicating the importance of syntaxin clusters in docking of insulin granules 
(Ohara-Imaizumi et al., 2007). Thus, SNARE proteins play significant role in 
insulin granule exocytosis and are important for modulating glucose 
homeostasis. 
 
1.4.2 Calcium sensors 
The fusion of vesicles to the plasma membrane and consequently the 
exocytosis of insulin granules is triggered by an elevation of the cytoplasmic 
Ca
2+
 concentration (Sudhof, 2012). In most cells that exhibit regulated 
exocytosis such as neuronal, endocrinal, neuroendocrinal and acrosomal cells, 
synaptotagmins have been identified as the primary calcium sensor proteins 
that couples increase in intracellular calcium ions to activation of exocytosis 
machinery for vesicle fusion. Synaptotagmins comprise an amino terminal 
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transmembrane region, a variable linker sequence and two C-terminal C2 
domains. The C2 domains harbor five calcium coordinating residues such that 
C2A and C2B domains bind to three and two calcium ions respectively 
(Sudhof, 2002). Several synaptotagmin isoforms have been identified and 
calcium dependent phospholipid binding has been reported for eight 
synaptotagmins (synaptotagmin-1, -2, -3, -5, -6, -7, -9, -10). The remaining 
synaptotagmins either lack the aspartate residues in their C2 domains that are 
required for binding calcium ions or are structurally too far apart to chelate to 
the calcium ions (Dai et al., 2004) and therefore cannot bind to calcium. 
Synaptoagmin-1, -2 and -9 are mainly expressed in brain and are involved in 
neurotransmitter release (Geppert et al., 1994; Sugita, Shin, Han, Lao, & 
Sudhof, 2002). Synaptotagmin-7 is abundant in neuroendocrine and endocrine 
cells where it regulates neuroendocrine and peptide hormone secretion 
(Gauthier et al., 2008; Gustavsson et al., 2008). Synaptotagmin-6 plays critical 
role in acrosomal exocytosis in sperm (Michaut et al., 2001; Tomes, 2015). 
Synaptotagmin-9 was recently identified to be involved in sex-specific 
regulation of follicle-stimulating hormone release (Roper, Briguglio, Evans, 
Jackson, & Chapman, 2015). Furthermore, multiple synaptotagmin isoforms 
might regulate distinct fusion events in same cells. For example, 
synaptotagmin-10 co-expresses with synaptotagmin-1 in olfactory bulb 
neurons and regulate insulin-like growth factor (IGF-1) secretion (Cao, 




Pancreatic beta cells also express various isoforms of synaptotagmins but this 
varies within species or between primary and clonal beta cell lines (Gao, 
Reavey-Cantwell, Young, Jegier, & Wolf, 2000; Gauthier et al., 2008; 
Gustavsson & Han, 2009; Iezzi, Kouri, Fukuda, & Wollheim, 2004). 
However, in all cases, synaptotagmin-7 (Syt7) seems to be the most abundant 
isoform with a role in glucose stimulated insulin secretion (Gauthier et al., 
2008; Gustavsson et al., 2009). Syt7 null-mutant mice exhibit impaired 
glucose tolerance and insulin secretion in-vivo and attenuated secretion from 
isolated islets despite normal insulin content (Gustavsson et al., 2008). Similar 
results were observed in clonal beta cell lines with decreased Syt7 expression 
following short hairpin (shRNA) knockdown (Gauthier et al., 2008). Taken 
together, Syt7 is a positive regulator of glucose-dependent insulin release. 
  
Since, deletion of Syt7 reduced insulin secretion by only about 50%, this 
suggests involvement of other calcium-binding proteins. Synaptotagmin-9 is 
also highly expressed in mouse and rat islets however its affinity to calcium is 
extremely low (10-30 uM) (Sugita et al., 2002). Although, synaptotagmin-9 
was reported to impair insulin release in rat islets (Iezzi, Eliasson, Fukuda, & 
Wollheim, 2005) and INS1E cell line (Iezzi et al., 2004) when silenced; no 
defects in insulin secretion was observed in the pancreas-specific 
synaptotagmin-9 knockout mice (Gustavsson et al., 2010). Role of 
synaptotagmin-3, -5, -6 and -10 isoforms in insulin secretion remains 
controversial. Synaptotagmin-3 (Brown et al., 2000; Gao et al., 2000; Gut et 
al., 2001) and synaptotagmin-5 (Gut et al., 2001; Iezzi et al., 2004) have been 
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shown to be a positive modulator of insulin release in insulin secreting cell 
lines. On the contrary, other studies demonstrate that recombinant calcium 
binding domains of synaptotagmin-3 is not effective in inhibiting calcium 
induced exocytosis in primary pancreatic islets (Gut et al., 2001). Moreover, 
specific role are yet to be assigned for synaptotagmin-6 and -10 in insulin 
secretion.  
 
1.4.3 Regulatory proteins 
In addition to core fusion proteins and calcium sensors, beta cells contain 
several regulatory proteins that orchestrate with fusion machinery and 
secretory granules to tightly regulate the exocytosis event. The major 
regulatory proteins include Rab proteins and its cytosolic effector molecules, 
Munc18 isoforms and motor proteins (Gerber & Sudhof, 2002; Ivarsson, Jing, 
Waselle, Regazzi, & Renstrom, 2005; Sudhof, 2013a). 
 
1.4.3.1 Rab and effector proteins 
Rab proteins constitute the large family of small GTPases that control various 
steps in membrane traffic, including vesicle formation, vesicle transport and 
membrane fusion via interaction with various cytosolic effector molecules. 
More than 60 isoforms of Rab proteins have been identified in humans 
(Stenmark, 2009; Zerial & McBride, 2001). Among those, Rab3 and Rab27 
are implicated in final steps of regulated exocytosis in beta cells (Kasai et al., 
2005; Yaekura et al., 2003). Rab3A null mice are glucose intolerant and 
exhibit loss of first phase insulin release (Yaekura et al., 2003) whereas Rab27 
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deficient mice exhibit reduced glucose dependent insulin secretion (Kasai et 
al., 2005) accompanied by delayed replenishment of readily releasable pool of 
insulin granules (Merrins & Stuenkel, 2008) suggesting isoform specific role 
of Rab3 and Rab27 in initial docking and replenishing of readily releasable 
vesicle pool respectively (Tsuboi & Fukuda, 2006). 
 
Rab proteins constantly switch between an inactive guanosine diphosphate 
(GDP)-bound form in the cytoplasm and an active guanosine triphosphate 
(GTP)-bound form on membranes. The Rab effectors selectively bind to the 
GTP-bound form and translate the signal from Rab proteins to regulate vesicle 
trafficking (Fukuda, 2008; Grosshans, Ortiz, & Novick, 2006). Although a 
large number of such effectors are present in beta cells, only few have been 
characterized for their role in insulin granule exocytosis. Granuphilin and 
Rabphilin3a (Rph3a) are Rab effectors associated with insulin granules 
(Brozzi, Diraison, et al., 2012). Knockout of granuphilin in mice islets results 
in increased accumulation of insulin containing vesicles close to the 
membrane but exhibits decreased fusion events (Gomi et al., 2005). While not 
directly addressed, this finding led to the hypothesis that docking could be a 
temporal brake for exocytosis to prevent incoming vesicles from being 
constitutively fused (Gomi et al., 2005; H. Wang et al., 2011). Rph3a on the 
other hand, involves in tethering of vesicles to plasma membrane in 
neuroendocrine cells, via its interaction with SNAP-25 (Deak et al., 2006; 
Tsuboi & Fukuda, 2005). However, its role in beta cells remains elusive due 
to its low abundance in islets. Moreover, overexpression studies in MIN6 
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suggested its role in PKA-dependent hormone secretion (Brozzi, Lajus, et al., 
2012). Regardless, its role in insulin secretion will be investigated in this 
thesis. 
 
Other important Rab effector proteins implicated in regulation of insulin 
secretion are Rab3-interacting molecule (RIM) (Iezzi, Regazzi, & Wollheim, 
2000; Yasuda et al., 2010) and No C2 domain (Noc2) proteins (Cheviet, 
Coppola, Haynes, Burgoyne, & Regazzi, 2004). While RIM was shown to 
interact with cAMP effector, exchange protein directly activated by cyclic 
AMP (Epac) to enhance cAMP-potentiated insulin secretion (Kashima et al., 
2001), Noc2 was found to associate with cytoskeletal associated protein-zyxin 
to enhance insulin release (Cheviet et al., 2004; Kotake et al., 1997). Together 




Munc18, also known as Mammalian Uncoordinated-18, is a mammalian 
homologue of unc-18 proteins in Caenorhabditis elegans. Its indispensable 
role in regulated exocytosis is demonstrated by complete abolition of synaptic 
transmission in Munc18 knockout mice (Hata, Slaughter, & Sudhof, 1993; 
Verhage et al., 2000). Munc18 engages in granule fusion process by 
stabilizing Syntaxin-1A at the plasma membrane (Jahn, Lang, & Sudhof, 
2003). Three isoforms of Munc18 have been identified; Munc18a, b and c. 
Munc18a and Munc18b pair with plasma membrane-localized syntaxin-1A 
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whereas Munc18c pairs exclusively with syntaxin-4. Islet β-cells express all 
three isoforms of Munc18 and thus regulate both syntaxin-1A and syntaxin-4 
based SNARE complexes (Wheeler et al., 1996). Different regulatory proteins 
like Munc13 (Kwan et al., 2006) and Double C2 protein (Doc2) (J. Li et al., 
2014) further interact with Munc18 to catalyze priming and assembly of 
fusion machinery. 
 
Munc18a is thought to mediate exocytosis of pre-docked granules that 
underlie first-phase secretion (Oh, Kalwat, Kim, Verhage, & Thurmond, 
2012). Likewise, Munc18b activate and induce the formation of syntaxin-3 
SM/SNARE complexes that mediate additional exocytosis of pre-docked 
granules as well as regulate granule-granule fusion in rat pancreatic beta cells 
(Lam et al., 2013). 
 
1.4.3.3 Motor proteins  
In the basal state, cortical actin networks hinder granule translocation from the 
cytosol to the plasma membrane. Following extracellular stimuli, motor 
proteins, kinesin and myosin transport the granules towards the plasma 
membrane where the relevant SNARE proteins engage to facilitate granule 
release (Burchfield, Lopez, Mele, Vallotton, & Hughes, 2010; Varadi, 
Ainscow, Allan, & Rutter, 2002). While both kinesin and myosin are 
important for vesicle transport, Myosin-Va (MyoVa), an actin based motor 
protein, involves in final steps of granule transport via its interplay with F-
actin. Mutation of MyoVa gene causes Griscelli syndrome in humans (Pastural 
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et al., 1997) and lethal phenotype in mice (X. Wu, Bowers, Wei, Kocher, & 
Hammer, 1997), both characterized by pigment dilution and neurological 
defects caused by impaired vesicle transport in melanosomes and neuronal 
cells respectively.  
 
MyoVa is composed of two identical heavy chains that dimerize in their coiled 
coil (CC) domain. In peripheral tissues such as adipocytes, MyoVa has been 
identified as insulin stimulated AKT2 substrate regulating ante-retrograde 
vesicle trafficking (Yoshizaki et al., 2007). MyoVa is enriched in insulin 
containing secretory granules and is involved in transport of granules from 
reserve pool to readily releasable pool to facilitate sustained insulin secretion 
(Brozzi, Diraison, et al., 2012). Consistent with this idea, reduced expression 
of MyoVa in pancreatic beta cells exhibited reduced expression of insulin 
containing granules in the TIRF zone along with disrupted transport and 
attachment behavior (Ivarsson et al., 2005; Varadi, Tsuboi, & Rutter, 2005). A 
study demonstrated that MyoVa directly interacts with docking proteins, 
Rph3a and Granuphilin to facilitate nutrient-stimulated hormone release 
(Brozzi, Lajus, et al., 2012). However, experiments directly addressing the 
immediate role of MyoVa in secretagogue-dependent insulin release are 
missing. Given the importance of motor proteins in granule transport, further 
investigations would warrant better understanding of vesicle dynamics and 





1.5 Potentiation of insulin secretion by GLP-1 
Under physiological settings, glucose plays a major role in triggering insulin 
release; however other nutritional cues and circulating hormones can also 
modulate the classical glucose-stimulated insulin secretion cascade. Of special 
interest is the incretin hormone, glucagon-like peptide-1 (GLP-1), that acts on 
beta cells to stimulate insulin secretion in a glucose-dependent manner 
(Baggio & Drucker, 2007). GLP-1 effect on insulin secretion was recognized 
when it was observed that compared to intravenous glucose load, isoglycemic 
oral load increases insulin secretion by almost 50-70% (Elrick, Stimmler, 
Hlad, & Arai, 1964). This phenomenon was later deemed as incretin effect. 
 
GLP-1 is derived from tissue-specific post-translational processing of 
precursor proglucagon gene. These proglucagon mRNA transcripts are 
expressed in the pancreatic alpha cells, intestinal L-cells and some 
hypothalamic neurons (Larsen, Tang-Christensen, Holst, & Orskov, 1997; 
Mojsov et al., 1986; Novak, Wilks, Buell, & McEwen, 1987). The differential 
post translational processing of proglucagon is dependent upon the tissue-
specific expression of prohormone convertase (PC) isoforms. In intestine and 
some hypothalamic neurons, enzyme PC1/3 acts on proglucagon to release 
GLP-1, in addition to GLP-2, glicentin and oxyntomodulin. In contrast, alpha 
cell expresses PC2 that cleaves the proglucagon precursor molecule to 
glucagon, glicentin-related pancreatic peptide and the major proglucagon 
fragment containing both GLP-1 and GLP-2 (Holst, 1997). Although adult 
alpha cell is thought to produce little GLP-1, induction of diabetes in rodents 
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leads to increased production of GLP-1 together with increased alpha cell 
expression of enzyme PC1/3. Moreover, this switch is beneficial to lower 
blood glucose levels and promote islet survival (Wideman, Covey, Webb, 
Drucker, & Kieffer, 2007). GLP-1, however has a very short half-life of 
approximately two minutes due to its rapid degradation by enzyme, dipeptidyl 
peptidase 4 (DPP4). DPP4 is a serine protease that is widely expressed in 
multiple tissues and circulates systemically as a soluble protein (Baggio & 
Drucker, 2007). 
 
Oral nutrients such as glucose and fat are primary physiological regulators of 
GLP-1 secretion. The role of proteins in GLP-1 secretion is controversial with 
most reports suggesting relatively small or no contribution except glutamine, a 
highly abundant non-essential amino acid that has been demonstrated to 
stimulate GLP-1 release (Greenfield et al., 2009; Tolhurst et al., 2011). 
Consistent with the proximity of L-cells to neurons and microvasculature of 
intestine, GLP-1 secretion is also affected by neural and hormonal 
(acetylcholine and gastrin-releasing peptide) signals (Anini, Hansotia, & 
Brubaker, 2002; Brubaker, 1991; Roberge, Gronau, & Brubaker, 1996). One 
intriguing factor triggering GLP-1 secretion is Interleukin (IL)-6, an 
inflammatory cytokine. Diabetes and obesity are usually accompanied by 
activation of innate immune system reflected by increased level of 
inflammatory markers including elevated level of interleukins (Donath & 
Shoelson, 2011). Interestingly, interleukins are also released in response to 
exercise and it was demonstrated that elevated IL-6 post-exercise stimulated 
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GLP-1 secretion from intestinal L-cells as well as pancreatic alpha cells in 
mice leading to improved glucose homeostasis. Complementing this finding, 
both acute and chronic administration of IL-6 stimulated GLP-1 secretion both 
in vitro and in vivo, whereas neutralization of IL-6 reduced pancreatic GLP-1 
content and deteriorated glycemic control (Ellingsgaard et al., 2011). 
 
GLP-1 has numerous biological actions (Drucker, 2015). In beta cell, it binds 
to GLP-1 receptor (GLP-1R) to directly enhance insulin secretion. 
Accordingly, genetic ablation of GLP-1R in mice results in glucose 
intolerance and impaired insulin secretion in response to oral and 
intraperitoneal glucose challenge (Lamont et al., 2012). Besides potentiating 
insulin release, GLP-1 also inhibits glucagon release from the alpha cells, 
increase beta cell proliferation and inhibit its apoptosis (Drucker, 2013; Egan, 
Bulotta, Hui, & Perfetti, 2003). Aside from its predominant effects on 
pancreas, GLP-1 also exhibits numerous extra-pancreatic effects. Infusion of 
GLP-1 inhibits gastric emptying and motility thereby slowing the rate of post-
prandial nutrient absorption (Schirra et al., 1996). It also potently inhibits food 
intake through activation of peripheral and central GLP-1 receptors (Knauf et 
al., 2008; Turton et al., 1996). Moreover, GLP-1 also stimulates hepatic 
glycogen synthesis and inhibits both hepatic gluconeogenesis and muscle 
glucose utilization (Ayala et al., 2009; Knauf et al., 2005). 
 
Given its role in maintaining glucose homeostasis, GLP-1 serves as attractive 
target for treatment of T2D. Most importantly, GLP-1 signaling in beta cells 
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manifest only after triggering signal has been produced by high blood glucose. 
The hierarchy between the triggering action of glucose and amplifying action 
of GLP-1 ensures that insulin is not secreted inappropriately under low 
glucose condition. Since commonly used drugs for treatment of diabetes like 
sulphonylureas directly target the ATP-dependent potassium channel complex 
and often result in hypoglycemia, therapies based on GLP-1 (long acting GLP-
1 analogues or inhibitors of GLP-1 degrading enzyme DPP4) make a more 
attractive target for diabetes treatment due to their dependence on glucose for 
amplification of insulin release (Ahren, 2009; Drucker, 2013). In fact, two 
new classes of drugs have been approved for lowering blood glucose in 
T2DM: an incretin mimetic (long lasting agonist of GLP-1 receptor) and an 
incretin enhancer (DPP4 inhibitor) (Gallwitz, 2005; Wilding & Hardy, 2011). 
Continuous GLP-1 treatment in T2DM can normalize blood glucose, improve 
beta cell function and restore beta cell glucose competence (G. G. t. Holz, 
Kuhtreiber, & Habener, 1993; Zander, Madsbad, Madsen, & Holst, 2002). 
Nonetheless, despite its beneficial effects, chronic activation of GLP-1R can 
have various side effects, thus a better understanding of GLP-1 action can lead 
to novel GLP-1 related treatment for T2D. 
 
1.6 Molecular targets of GLP-1 signaling pathway 
GLP-1 signaling is transduced through binding of GLP-1 to its cognate 
receptor in the beta cell membrane. GLP-1R is a ligand-specific, seven-
transmembrane domain G-protein coupled receptor. Binding of GLP-1 to the 
receptor facilitates the release of activated Gas subunit of the trimeric G-
22 
 
protein complex, which then activates plasma membrane-bound adenylyl 
cyclase to produce cyclic adenosine monophosphate (cAMP) (Doyle & Egan, 
2007; Thorens, 2004). cAMP serves as a secondary messenger that transduces 
extracellular signals from hormones and neurotransmitters to control diverse 
range of cellular processes. In beta cells, GLP-1R induced cAMP potentiates 
insulin secretion via two primary downstream effectors: Protein Kinase A 
(PKA) and cAMP-regulated guanine nucleotide exchange factor (cAMP-
GEF), Epac (Seino & Shibasaki, 2005). Extensive studies over the years have 
led to identification of substrates for both PKA-dependent and PKA- 
independent/Epac pathway (G. Holz, Chepurny, Leech, Song, & Hussain, 
2014; Seino & Shibasaki, 2005) however; many aspects of the mechanism of 
potentiation and its regulation remain obscure. 
 
PKA independent pathway involves Epac signaling (de Rooij et al., 1998; 
Ozaki et al., 2000). Two isoforms of Epac protein have been identified, Epac1 
and Epac2. Both isoforms are expressed in beta cells; however, Epac2 plays a 
dominant role in GLP-1 induced insulin secretion (Leech, Holz, Chepurny, & 
Habener, 2000). Epac2 contains a guanine nucleotide exchange factor (GEF) 
domain that activates small G-proteins, Rap1 and Rap2, when bound to cAMP 
(Bos, 2006). Rap proteins bind to phospholipase C (PLC) to stimulate its 
catalytic activity. PLC catalyzes hydrolysis of phosphatidylinositol 4.5-
bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5-triphosphate. 
(IP3). While DAG stimulates protein kinase C signaling, IP3 mobilizes 
calcium from intracellular stores like endoplasmic reticulum. Together, these 
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actions result in highly localized calcium signal that promotes granule 
exocytosis (Branham et al., 2009). Consistent with this, Epac2 knockout mice 
exhibit reduced potentiation in first phase insulin secretion in response to 
GLP-1 agonist (Song, Mondal, Li, Lee, & Hussain, 2013). Furthermore, Epac2 
also associates directly with RIM2 and piccolo to enhance exocytosis by 
promoting insulin granule dynamics (Fujimoto et al., 2002; Shibasaki et al., 
2007). Of interest, sulphonylurea is a widely used antidiabetic drug and this 
was shown to directly interact with Epac to potentiate insulin secretion (Zhang 
et al., 2009), thus highlighting the possibility of Epac targeting in diabetes 
therapy.  
 
While the signaling involving PKA-independent/Epac pathway is more 
defined, the downstream targets of PKA-dependent pathway have not been 
fully understood. PKA consists of two catalytic and two regulatory subunits; 
together they form an inactive tetrameric holoenzyme. Binding of cAMP to 
the regulatory subunit allows dissociation of the complex, thus enabling 
catalytic subunits to phosphorylate substrate proteins. Recent studies have 
reported that PKA phosphorylates various proteins associated with the insulin 
granule secretory process to directly modulate exocytosis. Some of the known 






Table 1-1 PKA substrates identified in beta cells 
Proteins Site Validation Reference
Snapin Ser50 Mouse (Song et al., 2011)
Syt7 Ser103 Mouse (Wu et al., 2015)
MyRIP - MIN6 (Brozzi et al., 2012)




MIN6 (Sugawara, et al., 2009)
 
 
Snapin is a SNAP-25 binding protein and is phosphorylated by PKA at Ser-50 
(Chheda, Ashery, Thakur, Rettig, & Sheng, 2001; Ilardi, Mochida, & Sheng, 
1999). Snapin as a target of PKA was initially identified in neurons with 
essential role in vesicle exocytosis via direct interaction with SNAP-25 
(Chheda et al., 2001). Moreover, importance of snapin phosphorylation in 
GLP-1-potentiated GSIS in pancreatic beta cells was demonstrated using 
mouse model with pancreas specific deletion of PKA regulatory subunit-1a (Δ 
prkar1a) (Song et al., 2011). Prkar1a is abundantly expressed in pancreatic 
islets (Petyuk et al., 2008) and deletion of this subunit allows constitutive 
expression of PKA. Interestingly, snapin phosphorylation was reduced in 
diabetic islets and expression of phosphomimetic snapin mutant (S50D) in 
these islets could restore glucose stimulated insulin secretion (Song et al., 
2011). This finding provides a new perspective on how post translational 
modification can be targeted for therapy in diabetics.  
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Recently, Syt7 was identified as a target of PKA. PKA phosphorylates Syt7 at 
Ser103 (B. Wu et al., 2015). This finding indicates that Syt7, besides being a 
major calcium sensor in beta cells, also regulates PKA-dependent insulin granule 
exocytosis. In support of this, islets from Syt7 knockout exhibits impaired GLP-1 
dependent insulin secretion, whereas overexpression of mutant Syt7 that mimics 
phosphorylated Syt7 state (i.e. S103E) in the knockout islets completely rescued 
GLP-1 dependent impaired insulin release (B. Wu et al., 2015). These findings 
indicate that Syt7 can be directly activated by GLP-1 and likely serve to enhance 
GLP-1 dependent insulin secretion.  
 
Given that PKA signaling is tightly controlled in beta cells, its temporal and 
spatial regulation requires specialized subcellular compartmentation by 
scaffolding proteins. MyRIP is one such scaffolding protein for PKA. In beta 
cells, GLP-1 signaling leads to formation of complex involving MyRIP, MyoVa 
and Rab27 that enhances insulin granule exocytosis in response to GLP-1 
treatment by allowing phosphorylation of Rph3a (Brozzi, Lajus, et al., 2012). 
While Rph3a has been extensively studied in neurons (Deak et al., 2006; Joberty, 
Stabila, Coppola, Macara, & Regazzi, 1999; Lonart & Sudhof, 1998; Schluter et 
al., 1999) and neuroendocrine cells (Abdel-Halim et al., 1996; Tsuboi & Fukuda, 
2005; Tsuboi, Kanno, & Fukuda, 2007; Tsuboi, Kitaguchi, Karasawa, Fukuda, & 
Miyawaki, 2010), so far only one study (Brozzi, Lajus, et al., 2012) has indirectly 
indicated its role in granule exocytosis in insulin secreting MIN6 cells. However, 
given its role in docking of granules, we can envisage its positive role in granule 
exocytosis. Besides Rph3a, a Rab11 effector-Rip11 was also reported to be a 
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direct substrate of PKA that potentiates GLP-1 dependent insulin release in MIN6 
cells (Sugawara, Shibasaki, Mizoguchi, Saito, & Seino, 2009).  
 
By far, GLP-1 modulates granule exocytosis by PKA-dependent and PKA-
independent mechanism; however, it remains unclear whether cAMP signaling 
results in preferential coupling of extracellular signaling to either PKA- dependent 
or independent pathway. A-kinase anchoring proteins (AKAP) have been shown 
to anchor both PKA (Lester, Langeberg, & Scott, 1997; Welch, Jones, & Scott, 
2010) and Epac (Hong, Lou, Gupta, Ribeiro-Neto, & Altschuler, 2008; Nijholt et 
al., 2008) separately, which might indicate independent actions. However, Snapin 
on the other hand is phosphorylated by PKA and phosphorylation enhances its 
interaction with Epac, indicating convergence of PKA-dependent and independent 
cAMP signaling (Song et al., 2011). Conceivably, concerted actions of both these 
pathways enable GLP-1 to potentiate insulin secretion.  
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1.7 Aims and Objectives 
Protein phosphorylation is emerging as an important regulatory mechanism 
that couples signaling cascades generated from extracellular and intracellular 
signals to vesicle transport machinery. GLP-1 is a potent incretin hormone that 
accelerates stimulus secretion coupling in pancreatic beta cells via PKA- 
dependent phosphorylation of target proteins in the exocytosis machinery. Of 
interest, several studies have demonstrated independent targets of PKA in beta 
cells and their roles in the potentiation of insulin secretion. However, the 
downstream events following phosphorylation of target proteins culminating 
in enhanced insulin granule exocytosis is not clear. Thus, the overarching 
objective of the current study is to identify and characterize the role of 
phosphorylation dependent Syt7 binding proteins in insulin secreting cells. 
This will further contribute to the understanding of the mechanistic machinery 
underpinning GLP-1 mediated enhanced insulin granule exocytosis following 
PKA-dependent phosphorylation. To address this, the aims of this project are: 
 To identify phosphorylation dependent Syt7 interacting proteins 
(addressed in Chapter 3.2); 
 To characterize their functional role in GLP-1 mediated insulin 
secretion (addressed in Chapter 3.3 and 3.4); 
 To delineate the mechanism by which Syt7 and interacting protein 




Chapter 2  MATERIALS AND METHODS 
2.1 Animal studies 
The Syt7 mutant mice were generated as described before (Maximov et al., 
2008). Homozygous Syt7 and wild type littermates used in this project were 
obtained using a heterozygous breeding strategy. All animal-related studies 
were approved by A*STAR Institutional Animal Care and Use Committees 
(IACUC # 110683).  
 
2.2 Cell Culture 
HEK293T cells were cultured in DMEM medium supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum, 50 U/ml penicillin, and 50 µg/ml 
streptomycin (GIBCO, USA). MIN6 cells were cultured in high glucose 
DMEM medium supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum, 1 mM glutamate, 50 μM β-mecaptoethanol, 50 U/ml penicillin, and 50 
µg/ml streptomycin (GIBCO, USA). INS1E cells were kindly provided by Dr. 
C. Wollheim (Geneva, Switzerland). INS1E cells were grown in RPMI 1640 
medium (GIBCO, USA) containing 11 mM glucose and 2 mM L-glutamine 
supplemented with 10 mM HEPES (pH 7.5), 10% (v/v) heat-inactivated fetal 
bovine serum, 1 mM Na-pyruvate, 50 µM β-mecaptoethanol, 50 U/ml 
penicillin, and 50 µg/ml streptomycin (Merglen et al., 2004). Cells were 




2.3 DNA constructs 
Primers were designed to amplify the entire coding sequence of corresponding 
genes with myc or flag tag epitope at the N-terminus. When required, the 
primers also incorporated restriction endonuclease sites, to simplify the 
cloning process.  Directional cloning was used when possible so each primer 
pair incorporated two different restriction enzyme sites to ensure that the gene 
would be inserted into the vector in right orientation. The primers were then 
used in PCR reaction and DNA obtained purified by gel extraction. The 
primers used in the study are listed in Table 2-1. The phosphorylated site 
mutation was obtained using Quickchange II site-directed mutagenesis kit 
(Stratagene, USA).  
 
For all myc-epitope tagged vectors, the c-myc sequence (peptide: 
MEQKLISEEDL; nucleotide: ATG GAA CAA AAA CTT ATT TCT GAA 
GAA GAT CTG) was placed in frame immediately upstream of coding 
sequence. Similarly for flag-epitope tagged vectors, flag sequence (peptide: 
DYKDDDDK; nucleotide: ATG GAC TAC AAG GAC GAT GAC GAT 
AAG) was placed at the N-terminus to be in-frame of the coding sequence. 
For these N-terminal tags, the transcription start site (ATG) was placed at the 






Table 2-1 List of primers used for polymerase chain reaction (PCR) 
cloning and quantitative PCR (qPCR) 












































































































   
qPCR GAPDH  CAAGGTCATCCATGACAACT
TTG 
 
  GGCCATCCACAGTCTTCTGG  

















    
qPCR MyoVa CGATTTGCTGGATGAGGAAT  
  ACAGTTTTTGGGCCCATGT  
     
 
2.4 Glutathione S-transferase (GST) protein expression and 
purification 
The cytoplasmic domain of Syt7 DNA sequences encoding the linker and C2 
domains (amino acid 41 to amino acid 403) was amplified from wild type and 
phosphomutant PCMV5-Syt7 plasmid. Primers were designed to introduce 
Xba1 overhangs on the ends. The amplified product was ligated into pGEX-
KG vector linearized with Xba1 restriction enzyme. Insertion of the fragment 
was confirmed by restriction digestion and sequencing. Correct plasmids were 
then transformed into BL21 (DE3) competent cells for protein expression. 
 
2.4.1 Optimization of recombinant protein expression 
To ensure high quality protein production, at least four clones for each 
plasmid were grown in small scale in Luria-Bertani broth (LB broth) with 
ampicillin (0.1 mg/ml) till OD600 of 0.7 was attained, at which point isopropyl 
β-D-1-thiogalactopyranoside (IPTG) was added to induce protein production. 
Once the clone with highest protein expression was identified, further 
optimization was performed for the expression conditions. The expression of 
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proteins can vary greatly depending upon the concentration of IPTG used, 
time of shaking or the incubation temperature. To optimize these parameters, 
selected clones were shaken either for 6 h or overnight with 0.1 mM or 1 mM 
IPTG at both 25 °C and 37 °C. After induction, bacterial pellets were 
resuspended in 1x SDS sample buffer and analyzed by western blot followed 
by Coomassie brilliant blue (CBB) staining. 
 
2.4.2 Large Scale expression and purification 
Once the optimal conditions were determined, large-scale fusion protein 
purification was performed. PGEX-Syt7 wild type and mutant plasmids were 
transformed into BL21 Escherichia coli and induced with IPTG for 6 h at 25 
°C. The bacterial suspension was centrifuged at 4000 rpm for 20 mins and the 
pellets were frozen at -80 degree. Following day, bacteria pellets were 
suspended in suspension buffer (40 mM TRIS, pH 8.2, 200 mM NaCl) with 
1% triton containing 1 mM phenylmethyl sulphonyl fluoride (PMSF) and 
protease inhibitor cocktail tablet (Roche, Germany) and sonicated on ice using 
ultrasonic processor Vibra-Cell VCX130 (Sonics & Materials, Inc.) with four 
cycles of a 30 s pulse followed by 30 s break at 30% amplitude output for 2 
mins. The lysate was cleared by centrifugation at 14,000 rpm at 4 °C for 30 
mins. The supernatant was then incubated with pre-equilibrated glutathione 
sepharose 4B beads with 1 mM dithiothreitol (DTT) overnight at 4 °C. 
 
Following day, the beads were washed twice in suspension buffer, twice in 
suspension buffer with 50 mM CaCl2, three times in Tris-EDTA (TE) buffer 
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with 1 M NaCl followed by three washes in PBS. The extensive high salt wash 
was performed to remove nucleic acid contaminants from bacteria that have 
previously been shown to cause oligomerization or affect its interaction with 
other molecule (Ubach et al., 2001). The beads were stored in PBS containing 
1 mM PMSF and 10 mM NaN3 at 4 °C. Beads were freshly prepared prior to 
start of experiments and run on 10% sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) gel to check for any degradation and 
visualized using CBB dye. 
 
2.5 Preparation of brain homogenate 
Forebrain was collected from Syt7 knockout mouse and homogenized on ice 
in Buffer A (20 mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, 10 mM 
NaF, 1% Triton-X-100) containing 1 mM PMSF and protease inhibitor 
cocktail tablet (Roche). The homogenate was rotated in cold room for 2 h and 
the insoluble materials were removed by centrifugation at 14000 rpm at 4 °C 
for 30 mins. The total brain extracts was pre-cleared by further incubation of 
the supernatant with mixture of 0.125 ml of pre-swelled glutathione agarose 
and 0.125 ml of GST beads for 2 h in cold room. The cleared lysate was 
collected by centrifugation at 800 g for 2 mins. 
 
2.6 GST pull down 
Pre-cleared brain/MIN6 lysate was incubated with freshly prepared beads 
containing approximately 5 μg of immobilized GST fusion proteins with 3.5 
mM CaCl2 or 5 mM EGTA overnight in cold room. Following this, beads 
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were washed five times with buffer A with five-min incubation between each 
wash. The bound proteins were then eluted using 2x SDS-PAGE sample 
buffer and loaded on 10% SDS PAGE gel and resulting protein bands were 
visualized by coomassie staining. For mass spectrometric (MS) analysis, the 
proteins were eluted from the beads by boiling in fresh NuPAGE® LDS 
sample buffer (Invitrogen™) for 5 mins or by incubating with freshly prepared 
8 M urea buffer (containing 0.1 M ammonium bicarbonate) for 30 mins at 
room temperature with gentle agitation.  
 
For verification of protein binding, HEK293T cells were transfected with 
plasmid encoding tagged constructs and harvested after 48 h. Cell were lysed 
in 1.5 ml lysis buffer A containing protease inhibitors. Cleared supernatant 
was incubated with approximately 2 μg GST fused Syt7 protein immobilized 
on glutathione beads for 1 h at 4 °C with gentle rotation. Beads were then 
washed three times with same buffer and bound proteins were analyzed by 
immunoblotting with tagged antibodies. Beads bound to GST only were used 
as negative control. 
 
2.7 Western Blotting 
Samples were either freeze-thawed or sonicated (Labsonic, Sartorius, 
Germany) to ensure total lysis of cells. Total protein lysates were collected by 
centrifugation at 14,000 rpm for 20 mins at 4 °C. Protein concentration was 
determined by Bradford assay (Bio-Rad). Equal amount of cell lysates were 
denatured using 5X detergent sodium dodecyl sulphate (SDS) at 100 °C for 10 
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mins. Following denaturation, samples were resolved on 10% SDS-PAGE gel 
and transferred to nitrocellulose membrane (Invitrogen, USA) and blocked 
with 5% non-fat dry milk in PBS with 0.1% Tween-20 (PBS-T) for 1 h at 
room temperature. The membranes were incubated in optimized primary 
antibody concentration for either 1 h at room temperature or overnight at 4 °C 
before incubating in horseradish peroxidase-conjugated secondary antibodies 
(GE Healthcare, UK) for 1 h at room temperature. Protein bands were 
visualized with enhanced chemiluminescence detection kit (GE Healthcare, 
UK). Beta tubulin (1:5000, Sigma) was used as a control to verify equal 
protein loading. The antibodies used in the study are listed in Table 2-2 below.  
 
Table 2-2 List of antibodies used 
Antibodies Isotype Source 
Anti-FLAG  Mouse Sigma 
Anti Myc, clone 9E10 Mouse Santa-Cruz 
Anti-Syt7 Rabbit Synaptic system 
Anti-Rph3a Rabbit Synaptic system 
Anti-Rph3a Mouse ECM bioscience 
Anti-P-Rph3a Rabbit Abnova 
Anti-SNAP23 Rabbit Synaptic system 
Anti-MyoVa Rabbit Cell Signaling 
Anti-Phosphoserine Rabbit Sigma 





HEK293T cells were transfected with plasmid encoding flag-tagged Rph3a 
along with myc-tagged Syt7 mutants using lipofectamine transfection 
following manufacturer’s protocol. After 48 h of transfection, cells were 
gently rinsed in ice cold PBS and lysed in Buffer A containing 1 mM PMSF 
and protease inhibitor cocktail tablet (Roche). The lysates were then rotated in 
cold room for 30 min followed by centrifugation at 14000 rpm for 20 min at 4 
°C. The supernatant was precleared using magnetic beads for an hour and the 
cleared supernatant was used for immunoprecipitation with anti-myc 
conjugated magnetic beads. Bound complexes were washed extensively with 
same buffer and eluted with 2x SDS loading dye. The eluate were loaded on 
10% SDS PAGE gel and probed for myc or flag antibody. 
 
For endogenous coimmunoprecipitation, MIN6 cells were grown to 
confluency (around 2 X 10
7
 cells on 10-cm plate). On the day of treatment, 
calls were fasted for 2 h in Krebs-Ringer medium (KRH) containing 130 mM 
NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, and 2.56 mM CaCl2, 
supplemented with 1% bovine serum albumin (BSA) (w/v) and 3 mM D-
glucose and buffered with 20 mM HEPES-NaOH to pH 7.4 followed by 
treatment with either DMSO or 10 µM foskolin for 30 min. Forskolin activates 
adenylate cyclase and increases the intracellular concentration of cAMP 
thereby activating PKA signaling pathway. Similar to GLP-1, treatment of 
MIN6 cells with the aforementioned concentration of forskolin for 30 min 
results in phosphorylation of Syt7. Treated cells were rinsed in ice cold PBS 
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and harvested in 1.5 ml lysis buffer A containing protease and phosphatase 
inhibitors. The lysates were rotated end to end in cold room for 30 min, 
followed by centrifugation at 14000 rpm for 15 min. The supernatant were 
then pre-cleared using 25 µl magnetic beads for 1 h to reduce any non-specific 
binding of proteins to the beads. About 2 μg cleared supernatant was then 
rotated end to end with primary antibody overnight at 4 °C. On the following 
day, 25 μl magnetic beads were added to the lysate and rotated for another 3 h 
at 4 °C. Beads were washed three times with same buffer with five mins 
incubation in between the washes and then eluted using 2x SDS loading dye. 
Immunoprecipitates were then analyzed by immunoblotting with respective 
antibodies. Beads containing equivalent amount of IgG antibody was used as 
control. 
 
2.9 RNA Isolation and Real-time-polymerase chain reaction (PCR) 
Analysis 
Total RNA was isolated from INS1E or MIN6 cells or islets using an RNeasy 
kit (QIAGEN, Germany). Briefly, the cells were harvested in RLT lysis buffer 
and transferred to a Qiashredder column for complete lysis. Equal volume of 
70% ethanol was added to the lysate and transferred into the RNAeasy spin 
column. DNA contamination was removed by on-column DNase treatment 
(QIAGEN). After subsequent washing steps, purified RNA was eluted from 
the column and the concentration determined by Nanodrop (Thermo 




To determine the mRNA expression levels, 1 μg of total RNA was reverse 
transcribed using RevertAID cDNA conversion kit (Fermentas, USA) 
according to the manufacturer’s instructions. A standardized amount of 10 ng 
of cDNA was used for each PCR. Transcript levels were determined by 
quantitative RT-PCR using SYBR Green PCR master mix (Applied 
Biosystems, USA). For amplification, cycle parameters were adjusted to 1 
cycle at 95 °C for 10 mins followed by 40 cycles of tandem 95 °C for 30 sec 
and 60 °C for 1 min. To prevent amplification of genomic DNA, intron-
spanning primers were used (Table 2-1). The relative mRNA expression was 
calculated using comparative Ct method. Normalization was done to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene. 
 
2.10 Cell Transfection 
HEK293T cells were cultured in 10 cm plate at a density of 2x10
6
 cells a day 
before transfection. At the time of transfection, the cells were approximately 
70% confluent. Cells were subsequently transfected transiently using 
Lipofectamine 2000 reagent (Invitrogen, USA), according to the 
manufacturer's instructions. Briefly, plasmids and Lipofectamine 2000 were 
mixed together (4 µg DNA to 10 µl Lipofectamine) in Opti-MEM I reduced 
serum medium (Invitrogen) and complexes formation was allowed at room 
temperature for 20 mins before adding onto the cells. Transfection media was 
replaced with normal culture media after 6 h and cells were cultured for 2 days 




2.11 Lentiviral ShRNA constructs for knockdown studies 
For loss of function studies, shRNA mediated gene silencing approach was 
used. Specific shRNA sequences were expressed either in pLenti-L309 
(Sudhof T, Standford, USA) or in PLKO.1 (Addgene) vector. For Rph3a gene 
silencing, shRNA and scrRNA sequences were cloned downstream of H1 
promoter in L309 vector backbone using XhoI/XbaI restriction sites. For 
MyoVa knockdown, shRNA and scrRNA sequences were cloned downstream 
of U6 promoter in PLKO.1 vector using AGEI/EcoRI restriction sites. The 
corresponding scrRNA and shRNA target sequences are shown in table 2-3. 
The sense sequences are highlighted in bold and underlined; antisense 
sequences are underlined. The loop sequences are denoted in small caps and 
the terminator signals are denoted in red. 
Table 2-3 ShRNA constructs used in the study 











2.12 Lentivirus Packaging and Infection  
Lentiviruses were produced by co-transfecting lentiviral expression vector and 
packaging plasmids into HEK293T cells using Lipofectamine 2000 reagent 
(Invitrogen, USA). Viral supernatant was collected 48 h after transfection, 
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centrifuged at 1000 g for 5 mins and filtered with 0.45 μm filter. The viruses 
were concentrated by ultracentrifugation at 26,000 RPM for 2 h at 20 °C 
(Beckman Coulter Optima-L-100 XP, SW41 swinging rotor).  Cultured cells 
were infected with concentrated viruses in the presence of 8 μg/ml polybrene 
to enhance the efficiency of viral infection. Culture media containing the virus 
was replaced with fresh media 24 h after infection. Knockdown efficiency was 
assessed by qRT-PCR and western blot for mRNA and protein abundance 
respectively 72-96 h after viral transduction.  
 
2.13 Adenoviral overexpression 
Recombinant adenovirus encoding Rph3a was prepared using the AdEasy 
system. A DNA fragment encoding wild type and phosphomutant Rph3a was 
generated using PCR with primers containing Kpn1 and Xba1 restriction site 
(Table 2-1) and ligated into p-Adshuttle-CMV under the control of the human 
cytomegalovirus promoter. Insertion of genes were confirmed by restriction 
digest and sequencing. The shuttle vectors containing wild type and 
phosphomutant Rph3a were then linearized using PmeI restriction enzyme and 
transformed into recombinant proficient (RECA+) BJ21 competent cells 
containing pAdEasy-1 backbone vector to generate recombinant adenoviral 
plasmid. Successful recombination event produced tiny colonies in agar plate, 
which were linearized using PacI restriction enzyme. The linearized 
recombinant DNA was then ethanol immunoprecipitated and directly 
transfected into mammalian packaging cell line (HEK293T cells) to produce 
viral plaques. The transfected cells were readily monitored through green 
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fluorescence. Ten days after transfection, the adenoviral particles were 
harvested from the cells by repeated freeze thaw lysis method. Further 
propagation was done in HEK293T cells and harvested every 48 h till a 
concentrated pool of virus was obtained. Viral particles so obtained were 
aliquot and stored at -80 ºC. For overexpression studies, freshly picked islets 
were transduced with appropriate multiplicity of infection (MOI) of virus for 
24-48 h prior to functional assay. 
  
2.14 Glucose-stimulated insulin secretion (GSIS) 
Min6 cells were cultured in 12-well plates until 80-90% confluence (2x10
5 
cells/ well). Before the experiments, Min6 cells were fasted for 2 h in Krebs-
Ringer medium (KRH) containing 130 mM NaCl, 4.7 mM KCl, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, and 2.56 mM CaCl2, supplemented with 1% bovine 
serum albumin (BSA) (w/v) and 3 mM D-glucose and buffered with 20 mM 
HEPES-NaOH to pH 7.4. The cells were then washed and preincubated with 
same buffer for 30 mins. Next, cells were incubated with 500 μl KRH 
containing 3 mM glucose for 30 mins followed by stimulation with KRH 
containing 16.7 mM glucose or 10 μM forskolin to stimulate insulin secretion. 
Supernatants were retained after each stimulus and the amount of insulin 
secreted was estimated by Insulin Enzyme-linked Immunosorbent Assay kit 
(ELISA) (Mercordia, Sweden) following manufacturer’s guidelines.  Total 




2.15 Islet isolation and secretion assay 
Islets were isolated from heterozygous Syt7 mutant mice for adenoviral 
overexpression of Rph3a plasmid. Briefly, mice were sacrificed by cervical 
dislocation and the abdominal cavity was opened. The pancreatic duct was 
cannulated and 3 mL of 2 mg/mL collagenase P (Roche, Switzerland) was 
injected into the common bile duct for pancreatic digestion. The pancreas was 
then excised and incubated at 37 ºC for 15 min, followed by gentle shaking. 
The samples were then centrifuged at 900 G for 1 min at 4 ºC, washed with 
HBSS and filtered through gauze. The islets were then handpicked under an 
upright stereomicroscope and cultured overnight in RPMI 1640 medium 
supplemented with 11 mM glucose, 10% Fetal bovine serum (FBS), 1% 
penicillin and streptomycin. Subsequent experiments were handled in KRH 
supplemented with 1 mg/ml BSA, 3 mM D-glucose and 20 mM HEPES at pH 
7.4 (KRH buffer). For static insulin secretion assay, islets were starved in 3 
mM glucose KRH buffer for 60 mins followed by sequential incubation in 3 
mM glucose KRH buffer for 30 mins and KRH buffer containing various 
stimuli for another 30 mins. Incubation buffer was collected following each 
stimulus and the insulin released was measured using Mouse Insulin ELISA 
kit (Mercodia, Sweden). Following stimulation, islets were lysed by sonication 
in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1mM EDTA, 0.1% NP-40, 
supplemented with protease and phosphatase inhibitor) and the total insulin 
and protein content were measured.  
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2.16 Statistical Analysis 
Data were presented as mean ± SEM. Statistical analyses were made using 
two-tailed Student’s test or one-way ANOVA for group comparisons. The 




Chapter 3  RESULTS 
3.1 Phosphorylation of Syt7 by PKA enhances GLP-1 dependent 
potentiation of insulin secretion  
Exocytosis of insulin-containing secretory granules in response to extracellular 
stimuli is tightly coupled with sensing of high local concentration of calcium 
in the vicinity of membrane, which is facilitated by calcium sensing protein. 
Syt7 is a major calcium sensor in both primary beta cells and clonal cell lines 
and plays a crucial role in glucose stimulated insulin secretion (GSIS). In 
islets, deletion of Syt7 resulted in more than 50% reduction in both first and 
second phase of insulin secretion (Gustavsson et al., 2008). Consequently, 
Syt7 has been identified as the predominant regulator of insulin secretion. 
While Syt7 appears to be an essential calcium sensor in mediating GSIS, it 
was also identified as a phosphorylation substrate of PKA in beta cells. 
Treatment of HEK293T cells overexpressing wild type Syt7 with forskolin or 
GLP-1 analogue, exendin-4 resulted in robust increase in apparent size of Syt7 
when analyzed by western blotting suggesting post-translational modification 
(Figure 3-1B, third lane). This shift in molecular weight was abolished when 
the cells were treated with PKA inhibitor, H-89 (Light et al., 2002) indicating 
PKA dependent signal transduction pathway by which forskolin or GLP-1 
exerts their effect. Using series of truncation and point mutants, the 
phosphorylation site was identified to be at Ser103 in the linker region (Figure 
3-1A and B). Interestingly, Syt7 mice have defective GLP-1 mediated insulin 
secretion which could be rescued by adenoviral overexpression of wild type 
Syt7 but not phophodefective Syt7 mutant (Ser103--> Ala) suggesting the 
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importance of phosphorylation in GLP-1 mediated potentiation of insulin 
granule exocytosis (B. Wu et al., 2015). These findings are relevant for several 
reasons. Firstly, Syt7 seems to be the key target modulating both glucose-
dependent and PKA-dependent insulin secretion. Secondly, it provides 
important evidence on regulation of synaptotagmin by post-translational 
modification. Finally, it expands the scope of synaptotagmin from being a 
critical calcium binding protein to regulator of exocytosis. At this point, while 
phosphorylation of Syt7 seems to be essential for GLP-1 potentiation of 
insulin secretion, the mechanism behind this potentiation is yet to be 
understood.  
 
In this thesis, using biochemical and molecular approaches to identify 
phosphorylation-dependent binding partner of Syt7, I strive to understand the 
molecular basis of GLP-1 action on insulin secretion. 
 
3.2 Proteomic screening of phosphorylation dependent Syt7 
interacting proteins 
The ability of beta cells to respond quickly to varying flux of intra- and 
extracellular cues relies on the extensive network of protein-protein 
interactions thereby creating a dynamic regulatory system within the 
exocytosis machinery. As discussed earlier, cAMP/PKA augments insulin 
secretion via phosphorylation of Syt7. Phosphorylation occurs at Ser103 in the 
linker region of Syt7 which is highly conserved among different species 
(Figure 3-1A). Moreover, despite essential role of Syt7 in calcium sensing, its 
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-triggered exocytosis (B. Wu et al., 2015). This suggests 
that phosphorylation may result in Syt7 interaction with as yet unidentified 
target proteins in the beta cell exocytosis machinery. To study if 
phosphorylation of Syt7 results in dynamic interaction network, a proteomic 
screening was performed using GST fused Syt7 protein with phosphomimetic 




Figure 3-1 Schematic for identification of phosphorylation dependent 
Syt7 binding proteins 
 
A) Sequence alignment of Syt7 residues carrying phosphorylation site from 
human, mouse and rat. S103 amino acid residue is conserved among all three 
species. B) Representative western blot for shift in band observed with 
treatment of HEK293T cells expressing wild type Syt7 with forskolin 
indicating phosphorylation of Syt7 (third lane), S103E mimics the 
phosphorylated state of Syt7. C) Vector map of PGEX-KG encoding GST-
Syt7. C-terminal portion containing the linker region from wild type and 
mutant Syt7 were cloned into XbaI site of the vector to obtain GST tag at N-
terminus. Protein expression is controlled by IPTG inducible tac promoter. D) 
Optimization of parameters for purification of GST fusion protein. First and 
second lane are bacterial lysates before and after IPTG induction. Final lane 
shows Syt7 C2A fragment expressed in GST beads. E) Successfully purified 
proteins were used as bait to identify interacting protein from the brain lysate 
in presence or absence of calcium. Bound proteins were eluted and processed 





3.2.1 Expression and purification of GST-Syt7 
Phosphomimetic (Ser103 --> Glu, S103E) and phosphodeficient (Ser103 --> 
Ala, S103A) mutants of Syt7 were generated by site directed mutagenesis. 
Mutation of Serine103 to glutamate mimics phosphorylated Syt7 due to charge 
and structural similarity with phosphorylated serine. On the contrary, alanine 
mutation mimics phosphodeficient mutant due to lack of –OH group needed 
for substitution with phosphate moiety. These mutants (encoding the linker 
and C-terminus) were then cloned into PGEX expression vector to allow N-
terminal GST tag. Following successful cloning, vector was transformed into 
BL21 bacteria to allow expression of GST fused Syt7 protein. To avoid 
misfolding and aggregation of proteins during overexpression (Georgiou & 
Valax, 1996), following parameters were optimized prior to large-scale 
purification: optimal bacterial optical density (OD)600 before induction of 
protein expression, concentration of IPTG required and temperature and 
duration of induction. The optimal condition was determined to be induction 
of BL21 bacterial strain expressing Syt7-PGEX plasmid at OD600 of 0.7 using 
0.1 mM IPTG while shaking at 25 ºC for 6 h (Figure 3-1D).  
 
3.2.2 GST pull down and mass spectrometry for identification of Syt7 
interacting protein 
GST beads expressing wild type and mutant Syt7 protein were incubated with 
precleared brain lysate from Syt7 knockout mice in presence of CaCl2 or 
EGTA to monitor calcium dependent or independent binding. GST beads 
without any fusion protein were used a negative control. Bound proteins were 
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identified using two complementary approaches, namely SDS-PAGE gel-
based ID and shotgun MS/MS based ID. One batch of eluted proteins was run 
on SDS-PAGE and Coomassie-stained protein bands were excised and 
digested by trypsin for MS analysis. Other batch of bound proteins eluted 
using urea buffer was subjected to in-solution trypsin digestion before being 
analyzed by MS. The major hits obtained using the above analyses are listed in 
Table 3-1. Among these proteins, those with functions that are known to be 
involved in exocytosis pathway were chosen as putative Syt7 interacting 
proteins and analyzed for cellular function associated with binding. 
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Table 3-1 List of proteins identified in mass spectrometry  











14-3-3 protein CamKII RasGAP1




















3.3 Rph3a interacts with Syt7 in calcium and phosphorylation 
dependent manner 
Among the proteins identified, Rph3a is of high interest for Syt7 binding, due 
to its known involvement in granule trafficking (Deak et al., 2006; Fukuda, 
2008). In neuroendocrine cells, Rph3a binds to SNAP-25 and docks the 
vesicles to the membrane, thereby facilitating granule release. Conversely, in 
insulin secreting cells, Rph3a binds to MyoVa and regulates hormone 
secretion following PKA activation (Brozzi, Lajus, et al., 2012). Regardless, 
evidences demonstrating interactions between Rph3a and Syt7 in the 
regulation of insulin exocytosis are not directly assessed. To validate 
observations from mass spectrometry data, we sought to confirm its 
interactions in vitro and in vivo. 
 
3.3.1 Rph3a is expressed in insulin secreting cells 
Extensive studies have characterized the expression of Rph3a in neuronal and 
neuroendocrine cells. However, its expression in insulin secreting cells has 
been controversial (Coppola et al., 2002; Regazzi et al., 1996). To investigate 
whether Rph3a is indeed present in insulin secreting clonal and primary beta 
cells, I performed western blotting and quantitative polymerase chain reaction 
(qPCR) analysis of MIN6, INS1E and mouse pancreatic islets. Rodent MIN6 
(mouse) and INS1E (rat) are commonly used insulin secreting clonal cell lines 
that mimic primary beta cells (Poitout, Olson, & Robertson, 1996). Consistent 
with previous observations (Inagaki, Mizuta, & Seino, 1994), Rph3a protein 
was abundantly expressed in brain (positive control) and was also detected in 
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MIN6 cells (Figure 3-2A). The antibody used for detection recognizes amino 
acid 671-684 of rat/mouse Rph3a sequence and has been validated before 
(Schluter et al., 1999).  However, as reported earlier (Inagaki et al., 1994; 
Regazzi et al., 1996), Rph3a protein expression was undetectable in INS1E 
cells (Figure 3-2A) and islets, this could be due to relatively low abundance of 
this protein in these cells as evidenced by its low transcript level (Figure 3-2). 
Our finding is in agreement with the previous study that documents expression 
of Rph3a in pancreatic beta cells (Brozzi, Diraison, et al., 2012; Brozzi, Lajus, 
et al., 2012). Moreover, the presence of Rph3a in insulin secreting cell lines 






Figure 3-2 Rph3a is expressed in insulin secreting cell lines and primary 
beta cells.  
 
A) Western blot analysis shows a 75kDa band corresponding to Rph3a in 
MIN6 cells. Brain lysate served as a positive control for Rph3a. Tubulin was 
used as a loading control. B) qRT-PCR analysis of Rph3a transcript 
abundance in insulin secreting cell lines and primary islets. The transcript 
abundance of Rph3a was normalized to GAPDH, a housekeeping gene. Data 




3.3.2 Phosphorylated Syt7 exhibits enhanced binding to Rph3a 
3.3.2.1 Syt7 binds to Rph3a in vitro 
Following the confirmation of Rph3a protein expression in brain and MIN6 
cells, pull down experiments in mouse brain lysates was performed using 
phosphomimetic and phosphomutant GST-Syt7.  Bound proteins were eluted 
and analyzed by standard western blotting as mentioned in methods section 
(section 2.7). A 75 kDa band corresponding to Rph3a was observed in eluents 
from GST-Syt7 but not from GST only beads, indicating that the interaction 
between Syt7 and Rph3a is specific. Furthermore, greater binding was 
observed with phosphomimetic (S103E) GST-Syt7 beads compared to 
phosphomutant (S103A) GST-Syt7 beads (Figure 3-3A), suggesting that 
phosphorylation of Syt7 enhances binding to Rph3a.  
 
To further confirm the binding interaction between phosphorylated Syt7 and 
Rph3a, coimmunoprecipitation was performed. Coimmunoprecipitation is 
another widely used method to identify stable protein-protein interactions and 
involves co-expression of epitope tagged proteins in cell lines of interest. 
Epitope tagging simplifies the immunoprecipitation experiments due to the 
availability of high affinity antibodies for the tags. Since they are short 
sequences, they usually do not interfere with protein expression and function 
(Terpe, 2003). Plasmids encoding Rph3a constructs were kindly provided by 
Dr. Zhiping Pang (UT Southwestern Medical Center). Flag tagged Rph3a was 
co-expressed with either wild type or phosphomutant myc tagged full length 
Syt7 in HEK293T cells. Monoclonal antibody against c-myc bound to 
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magnetic beads was used to immunoprecipitate Rph3a in calcium or EGTA 
containing IP buffer. As observed in GST pull down, Rph3a bound slightly 
more strongly to phosphomimetic Syt7 than with phosphodeficient form 
(Figure 3-3B). Furthermore, Rph3a bound to Syt7 both in presence and in 
absence of calcium, however calcium significantly enhanced both Syt7 and 
Rph3a interaction, suggesting that Syt7-Rph3a binding is both 










Figure 3-3 Syt7 interacts with Rph3a in vitro 
 
A) Wildtype (WT), phosphodeficient (SA) and phosphomimetic (SE) GST 
Syt7 beads were used to pulldown brain lysate. Rph3a interacts with higher 
affinity to phosphorylated Syt7 (SE) compared to phosphodeficient (SA) form. 
B) Flag tagged Syt7 and Rph3a plasmids were coexpressed in HEK293T cells 
and c-myc antibody was used to pull down Rph3a in presence or absence of 
calcium (Ca
2+
). Rph3a binds to Syt7 in a phosphorylation and calcium 
dependent manner. C) Input shows equal amount of protein being loaded. 
Figures are representatives of two independent experiments.  
 
The GST-pull down and coimmunoprecipitation assay results described above 
confirm the interaction of Syt7 with Rph3a. Although both these methods 
provide evidence of in vitro binding, they do not necessarily reflect or 
recapitulate that these protein interact in vivo since in vitro studies only 
provide biochemical endpoints of multiple protein interactions under 
solubilized condition. Therefore, these interactions need to be demonstrated to 
occur in vivo. 
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3.3.2.2  Binding of Syt7 to Rph3a is promoted by PKA signaling in vivo 
To determine whether the Syt7-Rph3a interaction characterized through in 
vitro experiments occurred in real time scale of insulin release in physiological 
settings, coimmunoprecipitation experiments were performed in MIN6 cells. 
MIN6 cell was chosen for this set of experiment due to the higher abundance 
of Rph3a expression compared to other insulin secreting cell lines as discussed 
earlier in section 1.3.1. MIN6 cell line was originally derived from a 
transgenic mouse expressing large T-antigen of SV40 in pancreatic beta cells, 
and is one of a few cell lines that display characteristics of pancreatic beta 
cells, including insulin secretion in response to glucose and other 
secretagogues (Ishihara et al., 1993; J.-I. Miyazaki et al., 1990) 
 
To mimic endogenous PKA stimulation, MIN6 cells were treated with either 
DMSO or with 10 µM forskolin (FSK) for 30 mins. Forskolin, a potent 
activator of AC, rapidly increases intracellular accumulation of cAMP, which 
in turn activates PKA signaling (Eddlestone, Oldham, Lipson, Premdas, & 
Beigelman, 1985) that phosphorylates Syt7 at Ser103 position (B. Wu et al., 
2015). To further confirm phosphorylation, I used P-PKA substrate antibody 
that recognizes phospho-serine/threonine residues that are preceded by 
arginine at the -3 position (RXXpS/T), comprising the PKA recognition site. 
Indeed, forskolin stimulation for 30 min robustly increased the overall PKA 
phosphorylation in MIN6 cells (Figure 3-4A). Following treatment, 
endogenous Rph3a was immunoprecipitated using polyclonal Syt7 antibody. 
Clearly, Rph3a was immunoprecipitated only when the cells were treated with 
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forskolin indicating phosphorylation dependent binding (Figure 3-4B). Rabbit 
IgG was used as control for immunoprecipitation.  
 
To avoid issues with antibody cross-reactivity to target and cellular proteins, I 
performed reciprocal immunoprecipitations in similar treatment condition but 
this time endogenous Syt7 was immunoprecipitated using monoclonal 
antibody against mouse Rph3a. Similar observation was made whereby 
binding of Syt7 to Rph3a was observed only in presence of forskolin 




Figure 3-4 Rph3a interacts with Syt7 in vivo  
 
A) MIN6 cells were treated with 10 µM forskolin (FSK) for 30 min to 
stimulate PKA-dependent phosphorylation. P-PKA substrate antibody was 
used to confirm overall increase in phopshorylation of proteins. B) Polyclonal 
rabbit antibody against Syt7 was used to immunoprecipitate DMSO or 
forskolin treated MIN6 cells. Rabbit IgG was used as negative control. Rph3a 
was detected only in lane with forskolin treatment, indicating phosphorylation 
dependent binding of Syt7 and Rph3a. No band was observed in IgG control. 
C) For reverse coimmunoprecipitation, monoclonal antibody against mouse 
Rph3a was used to immunoprecipitate Syt7 from MIN6 cell lysates treated 
with or without forskolin. Syt7 was only detected in lane with forskolin 
treatment, confirming phosphorylation dependent interaction. Input shows 
equal amount of proteins being loaded. Figures are representative of two to 
three independent experiments. 
 
Taken together, these data confirm that Rph3a binds to Syt7 and 
phosphorylation of both proteins by PKA enhances their binding affinity. 
Notably, the amount of endogenous Rph3a protein that co-immunoprecipitated 
with endogenous Syt7 is relatively small. This is expected because only a 
small fraction of Syt7 is phosphorylated under the stimulated condition. 
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3.3.3 Phosphorylation of Rph3a further enhances binding to Syt7 
It is well established that Rph3a can be phosphorylated by calmodulin- and 
cAMP-dependent protein kinases in vitro and by PKA in neurons (Fykse, Li, 
& Sudhof, 1995; Lonart & Sudhof, 1998). The major phosphorylation site is 
Serine 234 (S234) located in the linker region between Rab binding amino-
terminus and the carboxyl-terminal C2 domains. Phosphorylation of Rph3a is 
thought to be involved in PKA induced activation of long-term-potentiation in 
neurons although no striking synaptic phenotype was observed in Rph3a 
knockout mice (Lonart & Sudhof, 1998). To confirm that phosphorylation 
occurs in exogenously expressed Rph3a, HEK293T overexpressing wild type 
Rph3a was treated with forskolin. Robust phosphorylation of Rph3a was 
observed within 15 mins of stimulation and was detected by p-serine antibody 
as well as previously characterized phospho-specific Rph3a antibody (Lonart 
& Sudhof, 1998) (Figure 3-5A).  
 
Since both Syt7 and Rph3a are phosphorylated by PKA, it is possible that 
phosphorylation of Rph3a would further enhance its binding with Syt7 to 
enhance PKA-dependent Syt7-mediated insulin release. To address this, I 
generated phosphorylation-deficient (Ser→Ala, phosphodeficient S234A) and 
phosphomimetic (Ser→Glu, phosphomimetic S234E) mutants of Rph3a using 
site-directed mutagenesis. Successful mutation was verified by sequencing 
using primers that span the phosphorylation region. These constructs were 
then overexpressed in HEK293T cells and GST-Syt7 beads were used to 
perform pull down assay. Notably, phosphomimetic Rph3a (S234E) readily 
62 
 
bound to GST Syt7 (S103E) as compared to phosphodeficient mutant (S234A) 
as shown in Figure 3-5B indicating phosphorylation of Rph3a further 
enhances binding to Syt7. 
 
 
Figure 3-5 Phosphorylation of Rph3a further enhances Syt7 binding 
 
A) Phosphorylation of Rph3a is induced by forskolin at Ser234 in the linker 
region. HEK293T cells overexpressing Flag Rph3a was treated with 10 uM 
forskolin for 15 mins. Robust phosphorylation was observed as detected by 
phospho-Rph3a (p-Rph) and P-Serine (P-Ser) antibody. B) Binding of Syt7 to 
Rph3a is further enhanced when Rph3a is also in a phosphorylated state. 
Ser234A and S234E are phosphodefective and phosphomimetic mutant of 
Rph3a respectively. Figures are representative of two independent 
experiments. 
 
Collectively, these results suggest that the phosphorylation of Syt7 and Rph3a 
proteins by PKA signaling further promote their association, which may in 




3.3.4 Syt7 interacts with C2A domain of Rph3a 
Rph3a contains a Rab binding domain (RBD) at the N-terminus followed by 
two tandem C2 domains at the C-terminus. Having observed the interaction of 
Syt7 and Rph3a in vitro and in vivo, the domain(s) of Rph3a necessary for 
Syt7 binding was investigated by GST pull down of Rph3a truncated mutants. 
Full length N-terminus Flag tagged Rph3a and the different Rph3a truncations 
carrying only the Rab binding domain, or the C2 domain were subcloned into 
PCMV5 vector (Figure 3-6A). Each of these constructs was transfected in 
HEK293T cells and their expressions were confirmed using antibody against 
Flag epitope (Figure 3-6C). Whole cell lysates expressing the truncated 
mutants were then incubated with GST Syt7 beads and the eluted proteins 
analyzed by SDS-PAGE and Western blot for anti-Flag antibody. Notably, 
only the fragment encompassing isolated C2A domain of Rph3a bound to 
Syt7. By contrast, fragments containing RBD or C2B domain failed to interact 
with Syt7 (Figure 3-6B), indicating that the C2A domain of Rph3a is primarily 





Figure 3-6 Mapping of Rph3a domain interacting with Syt7   
 
A) Schematic of Rph3a truncation mutants. Subscript numbers are indicative 
of amino acid positions. All sequences were cloned into PCMV5 vector with 
Flag epitope tag at the N-terminus of start codon. B) C2A domain of Rph3a 
binds to Syt7 but not the RBD or C2B domain. C) Input shows comparable 
expression of all the mutants. 
 
Taken together, current observations have provided strong evidence for 
phosphorylation dependent binding of Syt7 with Rph3a. Further understanding 
of the importance of Syt7-Rph3a interaction requires methods to study gain- 
and loss-of-function of interacting proteins. This is discussed in details in the 
following section.  
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3.4 Rph3a in regulation of GLP-1 potentiated insulin secretion 
Although the significance of Rph3a in synaptic vesicle release has been 
largely debated due to lack of synaptic phenotype in knockout mice, in vitro 
studies in chromaffin and PC12 cells indicated its role in docking of granules 
(Deak et al., 2006; Fukuda, 2008; Tsuboi et al., 2007). Furthermore, Rph3a 
proteins are proposed to play a role in GLP-1 mediated hormone release from 
MIN6 cells (Brozzi, Lajus, et al., 2012). However, these observations were 
made in experiments involving overexpression of growth hormone, which may 
not reflect the ideal insulin secretion phenotype. Thus, the functional role of 
Rph3a in direct regulation of GLP-1 potentiated insulin release warrants 
further investigation. To address this, I performed knockdown of endogenous 
Rph3a protein from the MIN6 cells and studied its effects on insulin secretion. 
 
3.4.1 Lentiviral mediated knockdown of Rph3a impairs insulin secretion 
in response to forskolin 
To evaluate whether disruption of Rph3a function affects GLP-1 dependent 
potentiation of insulin secretion, Rph3a gene expression was silenced using 
lentivirus-mediated delivery of shRNA. Lentivirus is commonly used for gene 
delivery due to its ability to infect both dividing and non-dividing cells with 
minimal toxicity. Upon transfection, shRNA is transcribed via Pol III 
promoter and processed into active 20 to 25-nt siRNAs by Dicer. The siRNA 
strands get incorporated into the RNA-induced silencing complex (RISC) and 
bind to the target mRNA in sequence specific manner via complementary base 
pairing. Once bound, argonaute protein in the RISC complex cleaves the 
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bound mRNA. This leads to reduced levels of transcript that is available for 
translation by ribosomes and thus results in effective repression of target gene 
activity (Paddison, Caudy, Bernstein, Hannon, & Conklin, 2002). The 
schematic for shRNA design is illustrated in Figure 3-7. 
 
 
Figure 3-7 Schematic for generation of Rph3a shRNA construct 
 
A) Schematic illustration of shRNA construct designed for Rph3a knockdown. 
shRNA is expressed as a hairpin that consists of sense sequence (bold and 
underlined), followed by 9nt spacer, an antisense sequence (underlined) and a 
transcription stop signal for RNA polymerase III (in red). B) Map of L309 
lentiviral vector. shRNA sequence was introduced downstream of H1 
promoter using XhoI/XbaI restriction sites. The H1 expression cassette 
provides efficient RNA polymerase III-dependent transcription of shRNA.  
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ShRNA construct generated against Rph3a (Sh3) significantly decreased the 
endogenous level of Rph3a protein expression in MIN6 cells as shown in the 
immunoblot from infected cells monitored 96 h after infection (Figure 3-8A). 
A non-targeting-scrambled (Scr) control was used to control for potential off-
target effects of lentivirus infection.  
 
After establishing effective and efficient knockdown of Rph3a, the effects of 
Rph3a protein loss on insulin secretion in response to high glucose and 
forskolin treatment were assessed. Briefly, cells were fasted for 2 h in Krebs 
Ringer HEPES (KRH) buffer containing 3 mM glucose. The cells were then 
preincubated with same buffer for 30 mins, followed by incubation for another 
30 min with KRH containing 16.7 mM glucose and 16.7 mM KRH with 
forskolin. Amount of insulin secreted was estimated using Insulin ELISA kit 
(Mercodia, Sweden), the readings were normalized to total insulin content. As 
shown in Figure 3-8B, knockdown of endogenous Rph3a from MIN6 cells 
significantly impaired forskolin-induced insulin secretion. On the contrary, 




Figure 3-8 Knockdown of Rph3a diminishes insulin secretion in MIN6 
cells  
 
A) RNA interference mediated silencing of endogenous Rph3a in MIN6 cells. 
MIN6 cells were transduced with lentivirus expressing shRNA with non-
specific (Scr) or Rph3a specific (Sh3) sequences. Figure shows representative 
immunoblot of MIN6 extracts confirming reduction of Rph3a protein 
abundance 72 h after viral transduction. Tubulin remains unchanged. B) 
Insulin secretion in static culture conditions. Scr or shRNA infected MIN6 
cells were starved for 2 h in low glucose (3 mM) KRH and the amount of 
insulin secreted following high glucose (16.7 mM) and forskolin treatment 
were measured by ELISA. Silencing of Rph3a significantly reduced forskolin 
stimulated insulin secretion but had no effect in high glucose induced insulin 
release. Data are expressed as mean±sem, n=3. *p<0.05. 
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3.4.2 Adenoviral overexpression of phosphomimetic Rph3a in islets 
enhances GLP-1 potentiated insulin secretion. 
Since forskolin-induced insulin secretion in Rph3a knockdown cells is 
defective, it is conceivable that phosphomimetic Rph3a might enhance insulin 
secretion. To determine if Rph3a phosphorylation could play a positive role in 
driving GLP-1 mediate insulin secretion, adenoviral constructs encoding wild 
type and phosphomutant Rph3a were overexpressed in islets and insulin 
secretion in response to GLP-1 analogue-exendin-4 was evaluated. 
 
Modulation of gene expression in islet is particularly daunting due to their 
three dimensional structure. Pancreatic islets are organized into an organoid 
cluster with beta cells forming the core and alpha cells at the periphery. Most 
vectors used for gene delivery only infects the periphery of islets, however 
adenoviral infection has been demonstrated to infect both the periphery and 
core of islets thus making it the most potent and suitable gene transfer tool for 
primary islets (Mukai et al., 2007). The schematic of adenovirus generation is 
shown below (Figure 3-12). Briefly, recombinant adenovirus is produced by 
double recombination event between shuttle vector carrying gene of interest 
(Rph3a) and adenoviral backbone plasmid vector, pAdEasy-1. Viral plaques 
are then obtained from mammalian packaging cell line expressing linearized 
recombinant plasmid. Adenoviral particles are further amplified and directly 
used for infection of islets. The infection efficiency can be monitored by 





Figure 3-9 Illustration of cloning strategy for adenovirus overexpressing 
Rph3a 
 
WT/SA/SE Rph3a was first cloned into a shuttle vector, pAdTrack-CMV. The 
resultant plasmid was linearized by digesting with restriction endonuclease 
PmeI and subsequently transformed into BJ competent cells containing the 
adenoviral backbone plasmid pAdEasy-1. The recombinant adenovirus 
plasmids were digested with PacI to liberate both inverted terminal repeats and 
transfected into HEK-293 cells. HEK-293T cells express E1 early gene that 
allowing virus production from backbone pAdEasy vector devoid of E1 gene. 
Recombinant adenoviruses are typically harvested after 7-10 days by lysis of 
HEK293T cells. Adenovirus particles are further amplified in HEK293T to 
obtain concentrated pool of virus. 
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Islets were infected with the concentrated pool of adenovirus containing wild 
type and phosphomutant Rph3a. Protein expression was monitored 48 h after 
infection to monitor the efficacy of the virus. Western blot analysis with 
Rph3a antibody revealed a single 75 kDa band corresponding to Rph3a which 
was absent in non-infected cells (Figure 3-10A) thus confirming the 
functionality of the virus. Note that Rph3a is not detectable in uninfected cells, 
presumably due to low amount of endogenous Rph3a protein expressed in 
islets. 
 
For insulin secretion, isolated islets from Syt7 heterozygous mice was first 
infected with adenovirus overnight and allowed to recover for one more day. 
The overexpression was confirmed by visualization of GFP signal as well as 
by western blotting. On the day of analysis, islets were fasted in low glucose 
KRH for 1 h, and then stimulated with low glucose or exendin-4 for 30 mins. 
Supernatant was collected after each treatment and secreted insulin measured 
by ELISA. While overexpression of wild type Rph3a (WT) and 
phosphomimetic Rph3a (S234E) showed significant increase in insulin 
secretion with exendin-4 treatment, overexpression of phosphodeficient Rph3a 
(S234A) had no further enhancement in insulin release in response to exendin-
4 (Figure 3-10B). These data strongly suggest that phosphorylation of Rph3a 




Figure 3-10 Phosphorylation of Rph3a enhances exendin-4 potentiated 
GSIS 
 
A) Overexpression of wildtype (WT), phosphomutant (S234A) and 
phosphomimetic (S234E) Rph3a in islets for 48 h. Islets were lysed and 
lysates were analyzed by immunoblotting with indicated antibody. B) Islets 
overexpressing Rph3a were starved for 1 h in 3 mM KRH and the amount of 
insulin secreted following exendin-4 treatment was measured by ELISA.  
Overexpression of WT Rph3a and S234E mutant in islets exhibited 
significantly higher exendin-4 mediated insulin secretion. S234A did not 
potentiate secretion further. Data expressed as mean±sem, n=4. *p<0.05. 
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3.5 Investigating the potential molecular mechanism of Syt7-Rph3a 
binding in regulating PKA-mediated insulin secretion potentiation 
The observations obtained by far suggest that phosphorylation induced 
enhanced binding of Syt7 and Rph3a is important for GLP-1 mediated insulin 
secretion. How exactly this enhanced binding promotes secretion remains 
undetermined. The role of Rph3a in docking of vesicles has been well 
characterized in neuroendocrine cells by its ability to interact with SNAP-25 
in the membrane (Deak et al., 2006). In beta cells however, it is thought to 
interact with MyoVa, a motor protein to enhance granule translocation to 
plasma membrane (Brozzi, Lajus, et al., 2012). Our proteomic data indicates 
that MyoVa is one of the common proteins that bind to both Syt7 and Rph3a. 
Moreover, MyoVa was eluted alongside phosphomimetic Syt7 (Table 3-1). 
Given the evidence of interaction of Rph3a with MyoVa in presence of PKA 
signaling, it was anticipated that Syt7, Rph3a and MyoVa could function as a 
molecular machinery to mediate granule trafficking following PKA 
stimulation. To test this hypothesis, I determine if MyoVa can interact with 
Syt7 and Rph3a upon forskolin treatment. 
 
3.5.1 MyoVa coimmunoprecipitates with Rph3a and Syt7 
Min6 cells were treated with DMSO or forskolin for 30 mins to examine if 
MyoVa coimmunoprecipitates with Syt7 upon PKA activation. Treatment 
with forskolin enhanced PKA phosphorylation. Endogenous MyoVa was 
immunoprecipitated from the untreated and treated cell lysates using 
polyclonal Syt7 antibody. IgA beads were used as control for 
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immunoprecipitation. Interestingly, MyoVa band was only observed under 
forskolin treated condition suggesting phosphorylation dependent binding of 
Syt7 to MyoVa (Figure 3-11). Input shows equivalent amount of protein 
loaded. 
 
Figure 3-11 MyoVa is coimmunoprecipitated by Syt7 upon treatment 
with forskolin.  
 
Coimmunoprecipitation assay of endogenously expressing Syt7 and MyoVa 
proteins from MIN6 lysates. Cells were treated with or without 10 µM 
forskolin treatment for 30 mins. Syt7 antibody was used to pull down MyoVa 
from cell lysates followed by immunoblotting with antibodies as indicated. 
Rabbit IgA was used as IP control. MyoVa coimmunorecipitated with Syt7 
upon treatment with forskolin. Input shows equal amount of protein loaded. 
Figure is representative of two independent experiments.  
 
3.5.2 Knockdown of MyoVa affects insulin secretion 
Since Syt7 bound to MyoVa in a phosphorylation dependent manner, 
functional role of MyoVa in GLP-1 dependent insulin secretion was assessed 
by lentiviral knockdown of endogenous MyoVa. ShRNA targeting the coiled 
coil (CC) domain of the MyoVa protein was expressed in PLKO.1 vector. 
Lentivirus expressing the shRNA was then used to silence MyoVa expression 




Figure 3-12 Schematic for generation of MyoVa shRNA construct 
 
A) Schematic illustration of shRNA construct designed for MyoVa 
knockdown. shRNA is expressed as a hairpin that consists of sense sequence 
(bold and underlined), followed by 9nt spacer, an antisense sequence 
(underlined) and a transcription stop signal for RNA polymerase III (in red). 
B) Map of pLKO.1 lentiviral vector. shRNA sequence was introduced 
downstream of U6 promoter using AgeI/EcoRI restriction sites. The U6 
expression cassette provides efficient RNA polymerase III-dependent 
transcription of shRNA. Infection efficiency can be readily monitored by 
visualization green flurescence.  
 
Knockdown of MyoVa following infection with lentivirus expressing shRNA 
was verified by real time qPCR which showed approximately 40% decrease in 
mRNA level 48 h after infection Figure 3-13A) and confirmed by western 
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blotting 72 h after infection (Figure 3-13B). Following knockdown, the role of 
MyoVa in insulin secretion was assessed by method as described above in 
section 1.4.1. Insulin secretion in response to forskolin treatment was found to 
be significantly lower in MyoVa knockdown cells (Figure 3-13C), with no 
effect in glucose dependent insulin release, indicating the role of MyoVa in 
PKA-mediated insulin granule exocytosis.  
 
Figure 3-13 Functional characterization of MyoVa knockdown  
 
A) qRT-PCR to confirm reduced transcript abundance of MyoVa with ShRNA 
to Scr control. B) Western blot confirming decrease in protein expression 
following ShRNA knockdown. C) Scr or shRNA infected cells were starved 
for 2 h in 3 mM KRH and the amount of insulin secreted following forskolin 
treatment was measured by ELISA. Silencing of MyoVa enhanced basal 
release but significantly reduced forskolin stimulated insulin secretion with no 
effect in high glucose induced insulin release. Data expressed as mean±sem, 
n=3. *p<0.05.  
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MyoVa is a crucial protein in beta cell exocytosis machinery with established 
roles in granule trafficking. Our current finding demonstrating Syt7 binding to 
MyoVa in a phosphorylation dependent manner together with decreased 
insulin secretion following MyoVa knockdown supports enhanced granule 
mobilization following phosphorylation of Syt7. Nevertheless, since Rph3a 
also binds to MyoVa, it is likely that these proteins together form a machinery 
to mobilize granules from the reserved pool to facilitate increased granule 
exocytosis following stimulation by PKA. 
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Chapter 4  DISCUSSION AND CONCLUSIONS 
4.1 Protein-protein interaction plays key role in PKA-mediated 
phosphorylation and GLP-1 mediated insulin release 
Glucose mediated insulin secretion (GSIS) serves as a primary mechanism to 
maintain normal blood glucose homeostasis, which is severely perturbed in 
diabetes. GLP-1 is a potent incretin hormone that potentiates insulin secretion 
in glucose dependent manner and normalizes insulin exocytotic defects in 
diabetic individuals.  Previous studies have demonstrated that GLP-1, via 
activation of PKA, can directly phosphorylate proteins in exocytosis 
machinery to enhance granule exocytosis (Brozzi, Lajus, et al., 2012; Song et 
al., 2011; Sugawara et al., 2009; B. Wu et al., 2015). Several PKA substrates 
have been identified in pancreatic beta cells that are phosphorylated during 
activation of GLP-1. For example, Snapin, a SNAP-25 binding protein was 
highly phosphorylated in mouse model with constitutive PKA activation 
(Song et al., 2011). Syt7, a calcium sensor in beta cell was shown to be 
phosphorylated in primary islets and insulin secreting cell lines in response to 
GLP-1 and PKA agonists (B. Wu et al., 2015). Similarly, Myosin- and Rab- 
interacting protein (MyRIP) was phosphorylated in insulin secreting cell lines 
that in turn enhanced its interaction with MyoVa and its receptor Rph3a 
(Brozzi, Lajus, et al., 2012). Relating the importance of protein 
phosphorylation to impaired insulin secretion, previous study has 
demonstrated that phosphorylated snapin level is decreased in diabetic rodent 
islets with impaired GSIS and overexpression of phosphomimetic Snapin can 
rescue the insulin secretion defect in these mice (Song et al., 2011). Likewise, 
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phosphomimetic Syt7 can rescue the defect in GLP-1 mediated insulin 
secretion observed in Syt7 knockout islet (B. Wu et al., 2015), underscoring 
the importance of posttranslational modification in granule exocytosis. 
 
Although the mechanisms underlying potentiation of insulin secretion by 
GLP-1 mediated substrate phosphorylation is not completely understood, 
some studies indicate regulation of protein-protein interaction of vesicle- and 
membrane-associated proteins within the exocytosis machinery following 
phosphorylation. In accordance with this hypothesis, phosphorylation of 
Snapin by PKA at Ser50 promotes interaction and assembly of SNAP-25, 
Collectrin and EPAC2 thereby converging both PKA-dependent and PKA-
independent pathway (Song et al., 2011). Similarly, phosphorylation of 
MyRIP brings together MyoVa and Rab27 to form a complex that ultimately 
enhances granule release by allowing phosphorylation of Rph3a (Brozzi, 
Lajus, et al., 2012). These findings relate to a dynamic regulation of protein 
interaction within the exocytosis machinery following PKA mediated 




4.2 Significance of current study 
Current study highlights the importance of protein-protein interaction as a 
critical node of molecular machinery underlying GLP-1 action consistent with 
the finding that Syt7 interacts with Rph3a upon activation of PKA signaling. 
Syt7 was shown to be phosphorylated by GLP-1 analogue exendin-4 in 
pancreatic beta cells and insulin secreting cell lines at Ser103. The site is 
positioned within the linker region connecting the calcium binding-C2 
domains with transmembrane domain. As the linker region is not well 
characterized, the significance for this phosphorylation in terms of molecular 
mechanism to regulate insulin secretion is not clear. In the current study, we 
identified Rph3a as a potential phosphorylation dependent interacting protein 
for Syt7 using mass spectrometry approach. Our hypothesis that Syt7 interacts 
with Rph3a is strengthened by several observations. Firstly, Rph3a is targeted 
to secretory vesicles (C. Li et al., 1994; McKiernan, Stabila, & Macara, 1996). 
Secondly, it binds to GTP bound Rab proteins that regulates vesicle 
recruitment to plasma membrane (C. Li et al., 1994). Lastly, it enhances 
stimulus dependent secretion in endocrine (Arribas, Regazzi, Garcia, 
Wollheim, & De Camilli, 1997) and neuroendocrine cells (Tsuboi & Fukuda, 
2005). Consistent with previous observations (Brozzi, Lajus, et al., 2012), the 
expression of Rph3a was confirmed in insulin secreting cells. In addition, 
using multiple approaches, I demonstrated that Syt7 binds to Rph3a in 




Interestingly, Rph3a can also be phosphorylated by PKA at Ser234 site in the 
linker region located between the Rab binding domain and C2 domains. 
Phosphorylation has been suggested to regulate neuronal activity during 
development in a synapse-specific manner (Foletti, Blitzer, & Scheller, 2001; 
Fykse et al., 1995). Using in vitro pull down assay, I demonstrate that Syt7 
binds strongly to phosphomimetic Rph3a compared to its phosphodeficient 
form. However, the truncation mutation analysis indicates that Syt7 binds to 
C2A domain of Rph3a. Despite the C2A fragment of Rph3a used in the 
experiment does not include phosphorylation site, the fact that this fragment of 
Rph3a still binds to Syt7 might be indicative that phosphorylation of Rph3a in 
vivo affects Rph3a localization to allow proximity with Syt7 for binding. This 
hypothesis is supported by an earlier finding by Foletti et al. that indicates 
reduced affinity of phosphorylated Rph3a to membrane (Foletti et al., 2001). 
Given that Rph3a rapidly shuttles between membrane and cytosol, 
phosphorylation then might be important for its role in vesicle mobilization for 
subsequent rounds of exocytosis. 
 
In the current study, using gain and loss of function assays, I demonstrate the 
importance of Rph3a in insulin granule exocytosis. Lentivirus mediated 
knockdown of endogenous Rph3a in MIN6 cells resulted in attenuation of 
forskolin mediated insulin secretion without affecting the glucose dependent 
insulin release, highlighting its importance in PKA signaling. Furthermore, 
adenoviral overexpression of wild type and phosphomimetic Rph3a in primary 
mouse islets exhibited enhanced exendin-4 mediated insulin release, whereas 
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phosphodeficient mutant did not potentiate secretion. In line with this, 
overexpression of phosphomimetic Rph3a in Min6 cells was shown to 
enhance growth hormone release following forskolin treatment (Brozzi et al., 
2012) although it should be noted that, insulin secretion was not assessed 
alongside in the same study. Accordingly, current observations further 
complement the observation that overexpression of phosphomimetic Rph3a 
facilitate GLP-1 potentiated granule exocytosis, thereby supporting the 
positive role of Rph3a in GLP-1 potentiation of insulin hormone secretion. 
 
Rph3a was originally identified in synaptic vesicles as an effector for Rab3A 
(Shirataki et al., 1993) and Rab3c (C. Li et al., 1994). However, Rph3a 
knockout mice did not exhibit defects in synaptic phenotype (Schluter et al., 
1999), suggesting that Rph3a does not directly regulate synaptic vesicle 
release in neuronal cells. In this context, Rph3a knockdown in MIN6 cells did 
not affect glucose-dependent insulin release. However, Rph3a deletion in 
Min6 cells significantly decreased GLP-1 dependent insulin secretion 
potentiation. This suggests that actions of Rph3a following PKA 
phosphorylation may preferentially regulate GLP-1 mediated insulin secretion. 
Given that Rph3a is targeted to Rab27 on the newly synthesized dense core 
granules (Tsuboi et al., 2010), and that sustained exocytosis response require 
continuous recruitment of newcomer granules (Gaisano, 2014), the role of 
Rph3a in selectively potentiating GLP-1 dependent insulin secretion is well 
justified. Previous studies suggest that Rph3a may be involved in vesicle 
transloction in both chromaffin and neuroendocrine cells (Arribas et al., 1997; 
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Chung, Takai, & Holz, 1995; Tsuboi & Fukuda, 2005). Moreover, these cells 
are shown to coexpress Rab27 and Rab3a (Fukuda, 2003). Consequently, it is 
speculated that Rph3a may act via Rab27 to regulate insulin granule 
exocytosis. Regardless, measures showing the direct interaction between 
Rph3a and Rab27 in facilitating insulin granule exocytosis are limited. Thus, 
further studies are required to validate this hypothesis. 
 
Previous studies have shown that Rph3a interacts with several proteins within 
the exocytosis machinery (M. Miyazaki et al., 1994; Tsuboi & Fukuda, 2005; 
Willshaw et al., 2004). Of particular importance is its interaction with MyoVa 
in MIN6 cells (Brozzi, Lajus, et al., 2012) that allows translocation of 
secretory granules from the reserved pool to the plasma membrane. Here, 
using pull down experiments, I demonstrate that MyoVa also 
immunoprecipitate with Syt7 upon activation of PKA. Consistent with the 
finding that MyoVa recruits large dense core vesicles to the plasma membrane 
(Brozzi, Diraison, et al., 2012), knockdown of endogenous MyoVa in MIN6 
significantly decreased forskolin mediated insulin release, suggesting its role 
in insulin vesicle trafficking. 
 
Together these results support the notion that phosphorylation modification 
represents an important regulatory mechanism that enhances insulin granule 
exocytosis by bringing together proteins essential for recruiting the granules to 
the plasma membrane such that more vesicles are made available for release 
following sustained stimuli by PKA.  
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How does phosphorylated Syt7 binding to Rph3a and MyoVa explain 
GLP-1/PKA function? 
Various models have been suggested for probable action of PKA. One model 
suggests that PKA renders granules within the readily releasable pool to be 
more sensitive to the stimulatory action of calcium thereby increasing release 
probability (Skelin & Rupnik, 2011). However, electrophysiology studies also 
demonstrate increased refilling of granules to the releasable pool upon 
activation of cAMP (Renstrom, Eliasson, & Rorsman, 1997). In line with this, 
stimulation of secretion following activation of PKA seems to be independent 
of calcium influx since the peak and integrated calcium currents were largely 
unaffected by PKA activators in beta cells (Ammala et al., 1994). Our findings 
indicate that phosphorylated Syt7 binds to Rph3a as well as MyoVa, both 
proteins being involved in vesicle trafficking. This supports the latter 
hypothesis in which PKA mediated phosphorylation events could enhance 
granule mobilization. Moreover, although Syt7 is a calcium sensing protein, 
the phosphomimetic Syt7 exhibits similar calcium binding affinity as WT Syt7 
(B. Wu et al., 2015), thus suggesting calcium-independent mechanisms for 
GLP-1 potentiation of insulin release. Together, these findings echo 
acceleration of granule mobilization in response to PKA activation as the 






4.3 Future work 
Within the scope of this thesis, it is evident that GLP-1 mediated exocytosis 
involves dynamic regulation of protein interactions that in turn enhance insulin 
release. However, further investigations are needed to address the potentiation 
of GLP-1-mediated insulin release in beta cells. Most importantly, GLP-1 also 
activates Epac signaling pathway that acts independent of PKA signaling. 
Moreover, Syt7 phosphorylation at Serine-103 is selective to PKA as Epac 
activator 8-CPT-2’-O-Me-cAMP failed to induce phosphorylation of Syt7 in 
insulin secreting cells (B. Wu et al., 2015), indicating that Syt7 may not be a 
target for PKA-independent pathways. Snapin, a PKA substrate is found to 
interact with Epac to coordinate both PKA-dependent and PKA-independent 
pathways. Whether Syt7 acts upstream of these events remains to be 
elucidated. 
 
Current study mainly applied biochemical and cell biology approach to 
examine the mechanism of phosphorylated Syt7-dependent insulin release. To 
further delineate how Syt7-Rph3a affects regulated exocytosis of insulin 
granules, exocytosis response may be measured by high-resolution membrane 
capacitance studies in Rph3a knockdown cells including islets. In addition, the 
use of TIRFM to monitor real time dynamics of insulin granules exocytosis in 
cells with disrupted Syt7-Rph3a interaction would decipher if GLP-1 actions 





Equally intriguing would be the understanding of phosphorylated Syt7 
regulation in diabetic condition. This can provide impetus for designing 
therapies that directly target Syt7 to selectively enhance insulin release 
therefore bypassing the off target effects of GLP-1. With proper understanding 
of mechanisms underlying stimulus induced insulin signaling, this may offer 





Based on current work, a working model is proposed to explain the molecular 
mechanism of GLP-1 dependent insulin granule exocytosis, which is at least in 
part mediated by PKA-dependent pathway (Figure 4-1). Initiation of PKA 
signaling by GLP-1 binding to its cognate receptors in beta cell membrane 
leads to phosphorylation of Syt7. Phosphorylated Syt7 interacts with vesicle 
associated Rph3a and MyoVa upon activation of PKA signaling. Knockdown 
of either interacting proteins result in diminished PKA-mediated insulin 
secretion. Given the role of both interacting proteins in granule mobilization, 
PKA activation by GLP-1 likely enhances granule exocytosis by promoting 
granule translocation to the plasma membrane. While the current study 
highlights the importance of granule mobilization in GLP-1 induced insulin 
secretion, it also extends the role of Syt7 in beta cells from conventional 





Figure 4-1 Schematic illustration depicting molecular players in GLP-1 
potentiation of insulin secretion in beta cells 
 
GLP-1 acts on G-protein coupled receptor in the beta cell membrane and 
activates adenylyl cyclase. Activated adenylyl cyclase converts ATP to cAMP 
which activates PKA-dependent and Epac-dependent pathway. PKA 
phosphorylates various proteins in the exocytosis machinery to enhance 
insulin granule exocytosis. Most importantly, phosphorylation of Syt7 by PKA 
enhances its interaction with Rph3a and MyoVa which ultimately enhances 
insulin granule exocytosis possibly by increasing granule mobilization. Epac 
enhances exocytosis by drectly binding to snapin and to KATP channel. Epac 
also binds to Rap proteins to activate phopsholipase C that converts PIP2 to 
IP3 and diacylglycerol (DAG) which enhance insulin release by increasing 
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